account adjust acquisition-rel cost certain
signific item
merck competit posit line lung cancer clear posit uncertainti
includ januvia outlook competit market competit pressur isentress
zostavax thin pipelin spin newco enhanc risk given even greater
relianc keytruda believ risk balanc opportun remain market perform
stock
februari announc separ compani two part effect
innov portion repres total sale includ
oncolog anti-infectives/hospit januvia product newco sale
estim includ women biosimilar zetia/vytorin
diversifi brand provid high-level detail model attempt dissect
two part
forecast ep revenu ep look pois
gain combin compani revenu growth forecast
ep growth reflect januvia patent expir ep
compound-annual-growth-rate industri averag
keytruda approv tumor domin lung monotherapi
high patient base chemo-combo base
expect keytruda continu hold major share lung cancer
keytruda also strong posit melanoma bladder rcc longer term
new indic includ use adjuv set expect drive solid growth
checkpoint competitor new combo repres clearest risk estim keytruda
sale
hiv islatravir nrtti phase ii hold promis pend visibl combin
partner oncolog on-going studi lenvima lynparza note fruition
could occur also combin keytruda sever tki
pneumococc vaccin expect import contributor
gefapix inhibitor chronic cough phase inhibitor pathway
may use acut cough pain migrain endometriosi sleep apnea ipf
vericiguat phase reduc eject fraction hf cv outcom studi posit
disclos file time
pleas see page report import disclosur
februari merck announc would separ compani two part
effect innov portion repres total sale
includ oncolog anti-infectives/hospit januvia product newco
sale estim includ women biosimilar
zetia/vytorin diversifi brand compani provid high-level detail
split time mrk-remainco expect post acceler revenu growth
oper effici oper margin
maintain current dividend annual increas achiev
pay-out ratio time newco also expect pay dividend
receiv tax-fre dividend upon close use bd share
ep forecast
estim ep growth revenu growth gross
profit margin forecast increas sg decreas
increas drive increas oper margin forecast net
non-oper expens increas higher interest expens
tax rate increas share count declin
time frameev ph ii data w/doravirin posit efficaci ia ii data monthli prep hiv primari complet dec ph data tnbc posit feb data nasopharyng carcinomaph data bladderkeytruda lenvimaphas data rcclynparza cediranib w/azn phase data ovarian cancergefapix ii data endometriosi painphas data chronic coughrecarbrioful ph data habp/vabp eecmid apr posit top-lin oct verti cv cv outcom data primari complet dec pneumococc vaccin phase datavericiguatful ph data hfref posit top-lin dec re-fil dose option rcv feb approv cscc pdufa file neo adjuv tnbc w/azn cn approv brcam breast canceru approval/eu file ovarian manten cancer pdufa approval/eu file brca/atm mcrpc profound pdufa file brcam ovarian cancerlynparza cediranib w/azn regulatori file ovarian cancerrecarbrioeu approv certain gram neg infect posit chmp dec approv habp/vabp pdufa w/azn eu file neurofibromatosi type approv neurofibromatosi type pdufa file hfref
cowen compani merck
combin compani estim ep growth
revenu growth gross profit margin forecast increas
sg hold flat increas drive increas oper margin
forecast net non-oper expens declin
tax rate hold share count declin
look ep growth revenu growth
gain due januvia patent expiri gross profit margin trend
except slight declin reach estim sg
increas increas annual oper
margin forecast increas year except
modest declin project forecast net non-oper expens decreas
year tax rate nudg year reach
share count declin per year ep peg
told merck ep compound-annual-growth-rate
merck guidanc forecaststot revenu oper expensesincreas low singl digit incom /expens expens expensetax rate count includ neg fx impact revenu neg fx impact ep mid-jan
compani report cowen compani
ye number yet avail merck cash/equival short-term
invest short-term debt long-term debt
estim free oper cf minu capital-expenditure increas
rang support annual dividend payment
well annual share repurchas
compani data cowen compani
pft salesop pft salesop pft total merck pre-tax equiti tax equiti pre-tax prioriti incom report tax mm mm cgr antibodi approv tumor type mani tumor types/combin qd antidiabet patent exp pedi exclus could add month crohn uc ra pa earli ra psoriasi patent expir biosimilar exposur marketsoth newer bridion simponi zerbaxa belsomra steglatro vax adempa belsomra gefapix criticaloth anti-infect oncologyanim mainli feed anim ou bravecto success flea/tick companion anim spin/split/sal tap merck remainco ezetimib gener vytorin gener modest growth thru newco women biosimilar diversfi brandstot ep versu industri averag ep
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
 riociguat solubl guanyl cyclas sgc modul approv eu pah cteph japan phase heart failur victoria ref-hf primari endpoint met part bayer nrx share patent expir pedi exclus could add monthsjanuvia patient expir exclus could add month januvia qd antidiabet competit threat given proven cv ertugliflozin diabet inhib w/pfe app mono combo w/sitagliptin metformin omarigliptin diabet qweek inhibitor market japan file plan diabet phase ii clinic holdtot market bridion market eu japan eu patent exp sugammadex anesthesia revers suvorex insomnia orexin neuropeptid approv us japan yet file eu schizophrenia phase iitot golimumab ra pa uc approv eu canada competit clip growthremicad crohn uc ra pa earli ra psoriasi patent expir biosimilar exposur marketstot ph chronic acut cough includ idiopath pulmonari fibrosi sleep apnea migrain endometriosi ph iitot
compani data cowen compani estim
 qd market blunt erosionisentress qd approv eu hiv integras inhibitor treatment resist nave approv gilead gsk tivicay pose competitionnoxafil patent expir eu patent expir posaconazol oral antifung approv prophylaxi oral candidiasi cubicin advers court decis allow gener first gener teva launch sale nv modest royaltiescubicin cubist acquir roch pegasys/copegu pressur new drug clip durat therapyintron support use oncolog applicationsribavirin/rebetol older modalityintron substanc patent exp formul patent exp settlement allow gener launch aug ou patent expiredcancida antifung qd iv new indic price share eros due competitioninvanz patent expir compound composit gener launch broad spectrum carbapenem oral im iv qdprimaxin emerg market-drivenprimaxin bolster sale effort blunt eros patent expir launch competit landscap pressureszepati launch eu japan competit landscap pressureszepati hepat grazoprevir proteas inhibitor elbasvir competit landscap ceftolozane/tazobactam ww right ex asia-pacif gram neg infect habp/vabp apprv difficil bezlotoxumab tx difficil associ diarrhea cdad approv medarex/ma biolog labspifeltro mono /delstrigo doravirin nnrti hiv qd dose approv letermovir cmv prophylaxi transplant patient roll-out tedizolid gram po infect launch phase habp/vabp hiv infect phase relebactam imipenem/cilastatin cuti/ciai approv older antibioticstot
compani data cowen compani estim
 approv tumor type includ melanoma lung renal chl bladder msi-hkeytruda eu approv melanoma lung chl bladder gastric nkeytruda antibodi mani tumor type melanoma phase solid tumor phase rcc phase saha cutan t-cell lymphoma roll-out underway clinic trial underwayemend aprepit substanc antagonist emesi patent exp oral iv franchis oral/ivtemodar teva launch gener gener japan pat exp eu temodar chemotherapeut aa gbmazn lynparza/selumetinib record sale net cog sg record lineeisai lenvima record sale net cog sg record linetot competit gsk shingrix prompt zostavax declin sale reflect dissolut spmsd jv ad herp zoster vaccin adult year singl sq dose plu booster investigatedproquad mmr ii varivax mmr ii varivax sale reflect dissolut spmsd jv ad mmr ii varivax support health initi demand buy patternsrotateq sale reflect dissolut spmsd jv ad rotaviru vaccin oral liquid good safeti profil market ww competit gskgardasil/gardasil approv year old femal male sale gardasil two dose approv fda/cdcgardasil/gardasil sale reflect dissolut spmsd jv ad approv two dose regimen china launch boostsgardasil/gardasil hpv vaccin borrow cdc stockpil refil
compani data cowen compani estim
 hexaval combin pediatr vaccin approv eu pneumoconjug vaccin phase valent tough competit ebola vaccin approv cytomegaloviru vaccin phase respiratori syncyti viru rsv phase iipneumovax use dose post prevnar boost tie birth cohortpneumovax support integr spmsd jv marketspneumovax pneumococc vaccin adultstot total healthlivestock leader vaccinescompanion anim bravecto oral approv may key driver line extens launchinganim boost smaller acquisit antelliq cattl monitor close anim bravecto numer therapeut productsanim line estim anim market growth remainco total sale
compani data cowen compani estim
 zetia lipitor market eu market cozaar/hyzaar arb hypertens gener competitionzetia patent expir glenmark enter month exclusivityzetia patent expir gener launch ezetimibevytorin exclus laps patent expir lost patent case euvytorin ezetimibe/simvastatin improve-it achiev endpoint garner fda labelintegrilin revenu repurchas milleniumzocor cholesterol reduct patent expir develop patent expir littl eros japan despit patent lapsetot antidepress patent expir januari major sale ex-u maxalt/maxalt mlt patent expir maxalt/maxalt mlt patent expir eumaxalt/maxalt mlt agonist anesthesia patent expir approv market countriestot
compani data cowen compani estim
implanon/nexplanon patent expir patent expir implant contracept patent expir juli progesteron/estrogen market eu exclus pursu corifollitropin alpha infertil market eu exclus pursu nuvar patent expir april first gener launch contracept vagin contracept patent expir septemb aq aq aq follitropin beta inject patent expir june oral contracept patent expir decemb contracept patent expir septemb oral contracept patent expir march contraception/women gener launch over-the-counter product also pressurenasonex gener eu allerg rhinitisdulera asthma market copd longer pursu dulera launch copd four market asthma market dulera mometasone/formoterol ics/laba twice daili competit pressuressingulair patent expir patent expir eu includ month pedi exclus japansingulair asthma/allergyasmanex market asmanex market countriesasmanex asthma dri powder qd inhal corticosteroid patent devic formul expir beta agonist asthma cfc hfa completeclarinex small market retainedclarinex claritin rx/otc sold bayer ag tax part consum transact close claritin/clarinex older product europetot
compani data cowen compani estim
 psoriasi moder potenc steroid patent exp compound cream lotion bph gener competit fosamax osteoporosi gener launch patent expir bald domin small acceler time upper lower gi recoveri post surgeri cubistbiosimilars/oth renflexi infliximab brenzi etanercept biosimilar total newco total sale sale guidanc includ fx impact
keytruda current approv follow advanc metastat
cancer melanoma nsclc chemo-combo regardless express
monotherapi patient express nsclc express
rcc inlyta head neck cancer bladder cancer
chl merkel cell carcinoma msi-high solid tumor gastric gastroesophag
sclc endometri cancer keytruda approv eu approv
japan includ approv nsclc adjuv melanoma msi-
high tumor keytruda launch see figur initi less impress
opdivo nivolumab sale vs given narrow label
second line lung lack approv io combin smaller number
approv indic keytruda close gap approv monotherapi octob
chemo-combin may nsclc came year ahead expect
opdivo yervoy approv approv keytruda inlyta rcc april
provid anoth boost also rapidli expand keytruda footprint
tumor type help earli fda approv pivot phase ii trial includ
dlbcl june cervic cancer june novemb
merkel cell carcinoma decemb first-mov statu lung earli
approv key strateg advantag allow keytruda surpass
opdivo vs
merck on-going keytruda trial includ combo trial
adjuvant/neoadjuv trial tumor type approxim
registr studi on-going includ metastat adjuv trial
earli stage pipelin includ dozen combin agent could enhanc
keytruda activ merck establish partnership
compani past trial consist demonstr keytruda shrink tumor
across histolog even endpoint miss statist signific merck believ
result repres wall data keep competit allay price pressur
estim keytruda sale
strateg posit keytruda opdivo tecentriq rhhbi imfinzi azn
adjuv set key factor shape competit landscap
beyond current pursu registr early-stag
adjuvant/neoadjuv trial tumor type includ melanoma tripl neg
gastric merck one adjuv approv melanoma earn year
launch indic also recent receiv approv bcg-
unrespons non-muscl invas bladder cancer across compani
neo adjuv trial on-going tumor type ph trial due read
wholesal acquisit cost wac mg vial keytruda
translat approxim per month
compani data includ accumul revenu franc germani recogn
cowen compani clinicaltri gov
keytruda becom standard care nsclc wt egfr monotherapi
patient high express tp base
combin chemotherapi patient low express
base recent result
broaden keytruda nsclc indic includ singl agent treatment patient
tp chemo combo like remain standard care
low impact nsclc competit posit unspectacular
result ph potenti azn ph poseidon
like mute keytruda also earn approv base
octob approv mrk keytruda chemo
nsclc regimen china provid ex-u boost
april keytruda label nsclc expand base phase keynote-
includ singl agent treatment patient tp
previous indic tp base june
present interim data statist comparison keytruda
paclitaxel pemetrex express os also
significantli improv patient tp express
tp express exploratori
analysi express group howev studi show modest hr
thu vast major surviv benefit appear deliv
group inde discuss note
similar differ bmi fail major differ
crossov allow despit new indic
therefor unlik dramat chang prescrib practic alreadi
establish howev still set bar higher front-
line io monotherapi virtu larger sampl size vs inclus
squamou histolog rigor primari endpoint os vs rel
addit receiv approv keytruda monotherapi stage
unresect nsclc patient inelig chemoradi much
smaller non-overlap group rel patient receiv azn imfinzi
current domin set
indication-tri namelinen primari endpointprimari completioncolorectalph keytruda adjuv carcinoma ph keytruda disease-fre surviv dor durat respons orr object respons rate os overal surviv progression-fre surviv rf recurrance-fre surviv pcr patholog complet respons ef event-fre surviv pd pharmacodynam
keytruda reduc risk death progress vs platinum-bas
show surviv benefit os vs despit fact
patient chemotherapi cross keytruda respons rate
keytruda chemotherapi benefit consist across
major subgroup modest femal never smoker
grade less frequent keytruda vs data world lung
show clinic meaning improv qualiti life vs platinum-bas
os data present show continu surviv
benefit keytruda vs chemo median os report chemo
arm month yet reach keytruda arm world confer
lung cancer octob mo report month keytruda
arm vs month chemo arm os data demonstr
continu surviv patient keytruda vs patient chemo
safeti outlook time point consist
previous report
merck data impress given compar arm platinum-bas chemotherapi
behav par histor benchmark benefit month
observ across subgroup os benefit observ despit cross-ov
rate modest favor imbal number former smoker may
amplifi benefit overal view data impress believ
repres first line nsclc patient base
express howev discuss caution may accur
consid patient brain met autoimmun diseas prior radiotherapi
egfr/alk mutat also exclud keytruda approv octob
 nsclc patient tumor express
egfr mutat well ahead pdufa eu approv indic
receiv late januari
may fda approv combin keytruda chemotherapi
carboplatin pemetrex previous untreat advanc non-squam nsclc
patient regardless express level base phase i/ii
cohort acceler approv conting upon confirm phase
all-com phase trial initi januari enrol non-
squamou nsclc patient regardless express level evalu
os co-primari endpoint januari announc top-lin result
combin keytruda chemo carboplatin
pemetrex met statist signific improv os co-primari
endpoint april present interim data
concurr publish result nejm impress data significantli
strengthen merck posit nsclc non-squam histolog august
fda approv label updat includ data subsequ
approv eu china grant septemb april respect
patient random receiv keytruda chemo alloc
treat chemo-alon alloc treat cutoff novemb
patient continu combin treatment patient
continu chemo cross permit chemo arm onto
keytruda monotherapi induct mainten phase cross
occur patient receiv in-studi pembro receiv off-studi
cohort patient appear evenli distribut across
express level patient design tp group less-than
greater-than equal-to
data biomarker-stratifi group shown tabl
includ os mo mpf orr dor keytruda chemo
month popul versu month
os data dual primari endpoint
os express
safeti consist previous demonstr grade
experienc combin regimen vs chemo regimen
all-caus lead discontinu slightli higher combin cohort
vs chemo cohort all-caus lead death
combin vs chemo frequent treatment group
nausea anemia fatigu constip
long-term follow-up present median follow-up
month data cutoff septemb os significantli increas
benefit realiz across express subgroup
os benefit appear definit subgroup
ci vs ci
ci one linger question regard trial whether
separ os curv would persist os benefit io/chemo
combin would diminish time median month os hr
increas slightli remain high bar efficaci strength
data underscor observ os benefit persist despit
patient chemo-onli arm receiv subsequ inhibitor
includ cross keytruda in-studi
phase evalu combin keytruda chemo vs
chemotherapi metastat squamou nsclc snsclc initi june
enrol patient os co-primari endpoint
carboplatin paclitaxel nab-paclitaxel chemotherapi backbon employ
arm may merck announc keytruda chemo combo met pre-
specifi secondari endpoint orr earli cohort particip
subsequ releas orr data combin cohort achiev orr
vs chemo alon also may
merck announc keytruda chemo hit co-primari endpoint achiev
significantli longer os chemotherapi alon interim analysi
octob keytruda chemo combin grant fda approv
squamou nsclc eu approv receiv march
full analysi interim data data cutoff april median
follow-up present summar tabl overal
across express level efficaci keytruda chemo sq nsclc
similarli impress data post grade trae occur
keytruda chemo treat patient vs chemo treat patient new safeti
concern observ cross popul
exclud still therapi
merck current hold approv indic
cowen compani
although import eclips stellar data phase
confirmatori discuss earn first approv
combin chemotherapi nsclc may fda grant acceler
approv keytruda-alimta-carboplatin combo non-squam nsclc
regardless express base cohort keytruda chemo
combo also ad nccn guidelin non-squam nsclc regardless
statu data present asco/esmo
keytruda pemetrex carboplatin cohort deliv respons rate
cohort present esmo patient random either
keytruda pemetrex carboplatin platinum-bas chemotherapi studi show
respons rate keytruda arm vs chemotherapi importantli
addit keytruda chemotherapi delay mpf month month
see tabl os benefit observ
small number event high cross-ov limit interpret fatigu
nausea vomit diarrhea rash liver enzym elev higher
subsequ data updat longer term follow-up present
/esmo present long-term follow-up data kn-
cohort patient evalu median follow-up month orr
keytruda/alimta/carbo arm vs alimta/carbo alon
longer combin median reach vs month
alimta/carbo group month combin vs
chemo alon patient express less
orr combin vs chemo alon patient
express orr vs chemo alon patient
express orr vs chemo alon patient
express orr combin vs chemo alon cohort data
updat addit five month follow-up median
month half patient keytruda/chemo respond treatment
compar one-third chemo alon orr vs mo still
reach keytruda chemo vs month chemo alon despit crossov
trend improv overal surviv continu seen keytruda chemo
keytruda steadi march up-lin nsclc made earli approv less directli
relev success drug becom truer standard care
regimen includ keytruda inhibitor secur first line set
number io-nav patient second line continu dwindl howev
full penetr yet reach keytruda still compet nsclc
opdivo nsclc approv octob keytruda receiv fda
approv use advanc nsclc patient progress
platinum-bas chemo egfr/alk inhibitor approv base result
present publish nejm
phase studi show impress result across differ histolog number
prior therapi greatest benefit observ patient express
efficaci data summar line previou studi fatigu
pruritu decreas appetit rash common
respons rate near strongli patient impress
arguabl superior monotherapi studi time howev given
quarter nsclc patient express opdivo alreadi
approv without biomark conting prospect restrict label
keytruda temper excit read
five-year follow-up nsclc patient present
repres longest-term surviv data yet examin keytruda
indic data cutoff novemb median rang follow-up
month estim os rate treatment-na
previous treat compar histor rate patient tp
rate respect orr ci
treatment-na ci previous treat although keytruda
alreadi becom soc nsclc long-term data strengthen case
use especi biomarker-select patient
phase ii/iii confirmatori trial compar keytruda docetaxel
patient fail prior platinum-bas chemotherapi full data updat
show keytruda reduc risk death strongli patient
patient patient pd-
express mo month keytruda vs month docetaxel pd-
patient mo month vs month docetaxel keytruda
better toler docetaxel grade trae keytruda
docetaxel data reflect keytruda label octob
 august eu
keytruda approv dose lower risk death
patient enrol compar opdivo
roch atezolizumab similar studi tabl view bit
underwhelm especi consid larger bristol
roch studi strongli patient keytruda approv dose lower
risk death compar bristol roch studi keytruda
perform line competit agent dose deliv
reduct death versu docetaxel patient strongli
possibl explan keytruda lower os benefit
patient enrol receiv least two line previou therapi
checkmat studi enrol exclus patient receiv one previou
line treatment roch poplar two line overal believ
data suggest keytruda favor differenti
march merck announc idmc recommend stop phase
trial head-to-head comparison keytruda versu ipilimumab yervoy
treatment nave advanc melanoma data present show one-
year os keytruda vs yervoy two-year os
keytruda vs yervoy one-year keytruda vs
yervoy two-year keytruda vs yervoy respons rate
keytruda vs yervoy grade keytruda vs
yervoy follow-up data show os
keytruda vs yervoy data median follow-up
month os rate keytruda vs yervoy treatment naiv
patient os rate keytruda vs yervoy analysi
also reveal median follow-up month post-complet keytruda
treatment patient achiev secondari endpoint
approv dose investig dose number patient enrol express cancer express cancer immun cell express cancer express cancer express cancer immun rhhbi
keytruda label updat decemb includ first line patient regardless
braf statu base first-lin approv subsequ grant
eu juli comparison across trial limit efficaci shown
keytruda appear line opdivo
show median month os orr given similar
efficaci monotherapi long term safeti efficaci combin io
agent ultim shape market share believ bristol edg given
combin opdivo yervoy alreadi market
present updat phase ib
treatment pembrolizumab monotherapi patient advanc melanoma
median follow-up month patient remain keytruda primari endpoint
orr achiev patient cr treatment-na
patient cr evalu secondari endpoint os rate
estim patient treatment naiv patient median os
month patient month treatment-na patient also evalu
secondari endpoint median month patient month
treatment-na patient median dor reach rang month
respond treatment-na patient rang month data cut
respons treatment-na respons still on-going
longest observ respons on-going month
merck publish updat jama april
subsequ present june data show respons rate
patient enrol among treatment nave one-year os
patient enrol treatment nave two-year os patient
treatment nave median os month total popul
month treatment nave patient keytruda well toler
patient experienc grade patient discontinu treatment
treatment relat jama editori note month mo
particularli impress given previou clinic trial involv patient
metastat melanoma report mo month keytruda label updat late
includ data
smr subsequ updat merck present phase ii data
compar pembrolizumab chemotherapi ipilimumab-refractori
melanoma studi pembro statist significantli reduc risk diseas
progress death arm hr ci
mg/kg arm vs chemotherapi hr ci
nine-month chemotherapi compar
juli china nation drug administr cnda approv keytruda
first therapi china treatment adult advanc melanoma
approv base orr data phase ib trial chines
patient howev result trial disclos phase ib keynote-
initi juli enrol chines patient singl group
assign receiv mg/kg pembrolizumab everi week primari endpoint
includ orr discontinu melanoma one fastest grow
malign cancer china increas annual rate becom one
lead caus death countri upon metastasi five-year surviv rate
advanc metastat melanoma chines patient estim
phase adjuv trial pursu keytruda
first read random double-blind studi keytruda versu
placebo treatment high-risk stage melanoma complet resect
studi enrol patient random primari endpoint recurrence-
free surviv rf all-com patient secondari endpoint includ
distant metastases-fre surviv dmf os also all-com patient
januari announc post-resect adjuv treatment keytruda
demonstr significantli longer rf placebo safeti profil
consist previou keytruda melanoma studi
data present april keytruda significantli
extend rf demonstr reduct risk diseas recurr death
compar placebo overal studi popul one-year rf
rate keytruda vs placebo popul month
rf rate keytruda vs placebo popul
patient keytruda also significantli prolong rf compar placebo
one-year rf rate keytruda vs placebo pd-
februari receiv fda approv treatment patient
resect high-risk stage melanoma base eu approv
grant decemb hold earli edg adjuv melanoma due
earlier approv rigor trial compar opdivo vs
yervoy plan follow-up studi phase
estim primari complet novemb
june keytruda approv us head neck squamou cell
carcinoma hnscc monotherapi combin chemotherapi
posit chmp opinion receiv octob approv base phase
trial patient recurrent/metastat
hnscc curabl local therapi prior system therapi
random receiv either keytruda monotherapi keytruda chemo cisplatin
carboplatin cetuximab chemo egfr inhibitor cisplatin/carboplatin
os evalu co-primari endpoint keytruda vs cetuximab chemo
keytruda chemo vs cetuximab chemo os assess
popul well patient express well
octob result present patient
cetuximab chemo month patient
os statist differ keytruda
monotherapi demonstr statist signific assess
popul confirm orr gener lower keytruda monotherapi arm
vs vs vs grade drug-
relat ae rate decreas keytruda vs
time analysi median os month keytruda chemo vs
month cetuximab chemo howev os statist
differ either cut-off popul confirm orr
treatment keytruda chemo combo demonstr longer mdor
vs month grade treatment-rel
final data present keytruda chemo exhibit superior os
total popul
keytruda monotherapi deliv superior os
total popul respons rate
keytruda chemo compar chemo alon keytruda monotherapi orr
lower vs grade ae rate keytruda alon
keytruda chemo cetuximab chemo deem
kol practice-chang base os improv total popul
keytruda chemo receiv broad label anticip strong uptak regimen
despit improv os patient benefit keytruda monotherapi
primarili deriv tumor opdivo anti-pd-
agent approv compani compar phase trial
opdivo yervoy vs cetuximab chemo pc aug
capit first-mov advantag data also consid
confirmatori keytruda approv
keytruda receiv acceler approv august use recurr
metastat head neck squamou cell carcinoma hnscc diseas progress
phase ib phase ii highli
refractori head neck cancer show respons rate
consist platinum failur platinum/ cetuximab failur hpv
hpv- patient common fatigu hypothyroid
rash grade enrol patient
fail platinum cetuximab show respons rate hpv
patient hpv- patient patient mpf
month mo month data compar favor histor
benchmark methotrex show respons rate month mo
fda grant broad label given test requir patient
need fail platinum cetuximab elig bit surpris
given patient enrol third liner fail platinum
erbitux initi cohort enrol patient
howev juli merck announc confirmatori
compar keytruda vs methotrex docetaxel cetuximab recurr cancer
narrowli miss primari endpoint os merck present updat data
april popul primari endpoint mo
month keytruda vs month soc key
secondari endpoint popul month keytruda vs
month soc
evalu key secondari endpoint patient express mo
month keytruda vs month soc mpf
month keytruda vs month soc patient
express mo month keytruda vs month soc
mpf month keytruda vs month soc
keytruda provid clinic meaning os benefit versu soc patient
recurr metastat hnscc enhanc benefit keytruda patient
tumor data file eu
pdufa origin set decemb chang acceler approv regular
approv howev file withdrawn post announc posit
phase trial result discuss instead
becam part file keytruda approv eu
cancer patient septemb base
keytruda inlyta vegf pdgf tki receiv approv rcc april
month ahead prioriti review pdufa date base impress data
present februari gu eu
approv grant septemb median follow-up month
combin achiev os co-primari endpoint assess
popul vs sutent median month keytruda inlyta vs
month sutent median os reach either
treatment group surviv achiev combo-tr patient
vs sutent-tr patient grade trae occur
patient keytruda inlyta result discontinu
combin grade trae occur patient sutent result
lower discontinu rate single-ag multi-tki anti-vegf pdgf c-
kit result keytruda inlyta combin consist across imdc risk
categori express group overal surviv benefit combin
achiev favorable- intermediate- poor-risk patient
well patient
bristol garner first-mov advantag compani
approv rcc includ opdivo mono approv novemb
opdivo yervoy approv april compar data bmi opdivo
outperform popul os result kol conclud
prompt overwhelm shift toward give keytruda inlyta
across line therapi long-term data emerg howev opdivo yervoy
may look better comparison could prompt eventu resurg
rcc current largest tumor type io repres overal
revenu gener opdivo revenu rcc
opdivo total revenu like swing favor mrk
keytruda
compar data express opdivo yervoy outperform
keytruda inlyta popul os combo
under-perform popul see chart patient compris
enrol vs albeit differ screen
assay may skew result howev draw conclus base pd-
statu may clinic use rcc patient routin screen
express least academ center could commun center send
broader assay expert estim express could
seen rcc patient depend assay
regardless best hope opdivo yervoy regain share rcc like lie
potenti io/io combin exhibit long-term surviv io/tki
one kol adam join shift toward keytruda inlyta
pend evid durabl complet respons whether respons
maintain off-treat visual pfs/os-curv tail view
keytruda inlyta combin io therapi parking-break cite
data suggest less-than-addit effect two agent less immune-rel
toxic keytruda inlyta vs keytruda single-ag therapi suggest
keytruda isnt exhibit full immun effect appear like pd-
group vs group suggest vegf inhibitor drive
activ keytruda inlyta stop patient progress
case singl agent patient stop keytruda monotherapi
continu respond kol look long-term follow-up data
month feel comfort switch keytruda inlyta
kol believ go much interest bavencio inlyta javelin
renal approv may tecentriq avastin phase
addit believ combin bmi opdivo yervoy phase
mrk lenvima keytruda phase may see
limit use due two key factor late entri crowd market lenvatinib
cabo consid dirtier tki increas toxic longer half-liv
inlyta
still would prefer pair keytruda one proprietari partner tki
phase initi septemb intend enrol
previous untreat rcc patient evalu primari endpoint
estim primari complet april eisai co-develop lenvima expect
top-lin result
keytruda approv chl bladder msi-high gastric cancer cervic cancer
chl merck present updat phase data respons
rate cr rate highli refractori classic hodgkin
lymphoma patient either adcetri resist and/or failed/not elig
autolog stem cell transplant drug safeti profil line
experi solid tumor confirmatori phase ii also present
show orr cr rate keytruda
receiv acceler approv pediatr adult relapsed/refractori chl
march eu approv adult r/r chl may phase
pivot head-to-head studi keytruda vs adcetri origin estim
primari complet decemb base os co-primari endpoint
januari extend estim primari complet decemb
unclear chang trial design prompt delay
data patient treatment refractori metastat carcinoma without
mutat call microsatellit throughout genom lead high
respons non- non- cancer includ gastric
endometri small bowel rectal cholangiocarcinoma mismatch repair-profici
cancer respons rate respons deep suggest microsatellit
instabl cancer particularli suscept blockad
base data fda grant keytruda breakthrough therapi design
may keytruda approv msi-h mismatch repair defici solid tumor
includ progress follow prior treatment merck state
test preval today patient screen msi-high howev
educ need rel signatur
data present phase ii studi msi-h
patient receiv two prior therapi msi-h non-
solid tumor patient receiv one prior therapi
orr pr non-crc orr
pr
bladder merck show keytruda reduc risk death
vs chemo mo month vs month platinum refractori
risk mo month vs month interestingli
initi mpf favor chemotherapi month vs month curv cross
keytruda vs chemo orr
keytruda vs chemo pembro better toler chemo grade
vs chemo view data impress given first studi
prospect show os benefit io bladder mo par nivo ipi
howev also note os benefit primarili driven
current/form smoker patient never smoke better chemo
respons rate appear par monotherapi studi cm-
follow-up data present show
averag month follow-up keytruda treatment reduc risk death
vs report dec keytruda treat patient mo
month month keytruda
vs chemo orr month remain keytruda chemo
phase ii trial keytruda respons rate comer
patient patient
updat data show orr cr pr median
durat respons reach patient express
orr cr pr patient express orr
may keytruda receiv acceler approv bladder cancer patient
elig cisplatin base bladder cancer month
ahead pdufa base merck fifth bladder market
second behind roch receiv approv april septemb
keytruda receiv eu approv cisplatin inelig bladder
septemb initi phase assess keytruda
/- chemo treatment metastat bladder cancer may fda alert
health care profession oncolog clinic investig public decreas
surviv associ use keytruda singl therapi clinic trial treat
bladder cancer patient low express
data monitor committe found low patient monotherapi arm
decreas surviv compar patient receiv cisplatin- carboplatin-bas
chemotherapi chang advers event profil keytruda
enrol subsequ chang keytruda monotherapi cohort
mono arm continu enrol patient two
arm trial keytruda chemo chemo-alon continu enrol all-
comer basi previous treat patient popul trial studi
estim patient chang current
keytruda label bladder estim primari complet may
os co-primari endpoint
also studi combin keytruda lenvima multi-tki vegfr
fgfr pdgfr phase i/ii solid tumor includ bladder
cancer cohort trial initi juli seek enrol total patient
evalu orr primari endpoint novemb interim data
bladder cancer patient receiv prior line therapi present
orr mpf month grade trae occur
patient report treatment-rel death common
trae kind proteinuria diarrhea hypertens
adjuv bladder octob present interim data phase ii
esmo evalu safeti efficaci keytruda
monotherapi high-risk non-muscl invas bladder cancer patient
respond bcg therapi trial initi februari intend enrol
patient cohort patient papillari diseas carcinoma situ
 patient papillari diseas without carcinoma situ co-primari endpoint
includ cr rate rate preliminari data patient cohort
present cr rate month
non-cr rate time analysi respond
patient on-going respons achiev cr month cr
last month longer follow-up present show
cr month januari keytruda receiv acceler approv
treatment patient bcg-unrespons high-risk non-muscl invas
bladder cancer nmibc posit adcom indic receiv one month
prior confirmatori phase on-going primari complet
cervic decemb merck file sbla keytruda treatment patient
recurr metastat cervic cancer diseas progress
chemotherapi whose tumor express base earli
data june fda grant acceler condit approv keytruda
cervic cancer base continu approv indic
may conting upon verif clinic benefit confirmatori trial
merck initi phase ii trial solid tumor januari
estim enrol patient estim primari complet june
studi evalu keytruda monotherapi sever tumor type orr
primari endpoint june present interim data
evalu patient show keytruda monotherapi orr confirm
merck present data cervic cancer cohort
patient determin posit august
data cutoff median follow-up durat month orr total
patient popul ci pr sd dcr
median dor reach rang month mpf
month ci mo month ci respons
patient tumor orr popul ci
respons on-going follow-up
initi phase trial posit tumor includ
patient cervic squamou cell cancer result present
demonstr achiev confirm orr pr mdor week
rate os rate result prompt
assess phase ii
esophag novemb announc phase trial
achiev os primari endpoint esophag cancer patient
score regardless histolog fda approv grant juli keynote-
assess keytruda monotherapi vs chemo paclitaxel docetaxel irinotecan
treatment patient advanc metastat diseas pd-
popul os sole primari endpoint orr secondari endpoint
os popul numer significantli improv keytruda
vs chemo primari os endpoint reach popul orr
secondari endpoint assess per statist analysi plan
standard chemo esophag cancer present
patient regardless histolog median os month keytruda
vs month chemo demonstr reduct
risk death os benefit also determin squamou cell carcinoma patient
mo month keytruda vs month chemo
howev os benefit seen popul mo
month keytruda chemo arm view result
encourag io treatment shown surviv benefit tumor
type howev signal larg carri express
addit studi phase keytruda chemo vs chemo
estim primari complet august look expand treatabl
gastric may merck publish updat phase ib data
keytruda advanc gastric cancer cohort lancet oncolog studi
enrol highli refractori popul patient fail
therapi patient evalu efficaci eight partial respons
median durat respons week mpf month mo month
toxic expect patient experienc immune-rel ae
editori paper conclud data promis given os current
soc keytruda deliv better os vs histor chemo vegf despit
septemb receiv acceler fda approv keytruda gastric
gastroesophag junction adenocarcinoma file base data phase
ii cohort present overal orr
cr pr pt orr
cr pr pt orr cr pr data line
phase trial continu promis given os current soc
also data gastric cancer cohort report
show orr pt pr pt
orr cr pt orr
median mo median os mo first time seen
data first line gastric appear solid
announc top-lin data piii pembro vs chemo
decemb indic keytruda meet co-primari endpoint os
ci addit co-primari endpoint
popul achiev statist signific complet
analysi publish lancet june orr keytruda vs
chemo dor month keytruda vs month chemo
mo statist differ keytruda month vs chemo month
patient os rate keytruda vs
chemo analysi determin keytruda could provid os benefit patient
express express
despit setback hit co-primari endpoint
forg forward phase evalu pembro vs platinum
treatment gastric gastroesophag junction adenocarcinoma patient
three arm keytruda
monotherapi keytruda chemo chemo alon primari endpoint pd-
os keytruda monotherapi month
found non-inferior chemotherapi month hit one
primari endpoint trial miss superior monotherapi
chemo combin arm furthermor mpf shorter keytruda monotherapi
month vs chemo month keytruda better toler howev
data may suffici drug retain approv unlik
file earlier line
januari phase ii investigator-initi trial memori sloan ketter
cancer center present phase ii trial evalu keytruda
herceptin fluoropyrimidin chemo treatment advanc
esophagogastr cancer trial initi novemb estim
primari complet date novemb assess primari endpoint data
evalu patient present orr
patient tumor regress mpf month
trae grade grade trae includ interstiti nephriti ast/alt
elev resolv steroid promis result prompt initi
phase test keytruda herceptin chemo advanc
gastric gej cancer octob estim primari complet june
assess os co-primari endpoint
februari announc neg top-lin result phase
evalu keytruda monotherapi vs best support care
although statist signific keytruda improv
os co-primari endpoint orr ci
keytruda vs ci placebo determin
subsequ anti-cancer therapi placebo arm like impact os result
keytruda acceler approv base phase ii may
question although fda hesit rescind condit
januari gi meet present result registr
phase ii trial trial evalu keytruda patient advanc
hepatocellular carcinoma previous treat chemotherapi
primari endpoint studi overal respons rate orr secondari endpoint
includ durat respons diseas control rate time progress os
treat patient continu therapi median follow month orr
cr pr respons describ similar across
subgroup differ etiolog median time respons month median
dor month respond estim respons
durat month diseas control rate interim
median month median os reach howev
os rate respect treatment-rel occur
patient grade occur death ulcer
esophag despit lack compar arm report seriou includ
death result appear favor in-lin result azn trial
 approv grant novemb trial on-going
timelin final data disclos
keytruda also studi combin lenvima phase leap-
pc base phase combin receiv
breakthrough design fda juli
pmbcl decemb merck present posit data phase ii
rare liquid tumor includ t-cell lymphoma primari
mediastin larg b-cell lymphoma pmbcl t-cell lymphoma lymphoma
keytruda deliv heavili pretreat patient mycosi fungoid
sezari syndrom safeti line prior studi except unexpect skin
flare reaction result higher rate discontinu respons
rate appear particularli impress given opdivo shown similar studi
pmbcl keytruda deliv patient relaps refractori
pmbcl inelig fail prior autolog stem-cel transplant asct
patient achiev cr patient pr median follow-up
month respons on-going pmbcl remain small commerci opportun
given repres nhl june keytruda receiv approv r/r
sclc may merck initi phase trial keytruda chemo
combin etoposide/platinum extens stage sclc trial enrol
patient random arm keytruda chemo chemo-alon evalu dual
primari endpoint os januari announc trial met
miss os hr ci statist signific
interim analysi os improv benefit reach statist
signific hr ci
keytruda receiv condit approv june sclc base pool data
cohort cohort june
merck present data phase ii trial solid tumor
includ sclc patient interim data show orr cr pr
median dor reach patient dor month median
month rate median os
month os rate patient
orr cr pr month rate
rate mo month os rate
os rate patient orr cr pr
month rate mo
month os rate keytruda
demonstr promis orr overal popul larg carri favor
respons express
tnbc phase studi keytruda chemo vs chemo alon
mtnbc on-going estim primari complet decemb data
expect earli os co-primari endpoint may
publish updat data jco demonstr orr
patient posit tnbc median durat respons
reach three five respond therapi month rang
week median time respons week rang week
month advers event consist previous report safeti
data pembrolizumab patient discontinu pembrolizumab due advers
event one treatment-rel death report patient rapidli
progress diseas due dic dissemin intravascular coagul
thrombocytopenia decreas blood fibrinogen
data phase ii studi tnbc present
cohort heavili pretreat orr cr pr
mpf month mo month cohort
orr cr pr mpf month mo
reach dor month month manag
safeti profil patient experienc grade trae depend
line treatment includ back pain fatigu hyponatremia hypotens
migrain launch phase trial tnbc announc may
phase studi keytruda monotherapi vs chemo
mtnbc fail meet primari os endpoint
also posit data phase ii i-spi trial evalu keytruda
chemo neoadjuv patient tnbc breast cancer
present keytruda chemo combo increas patholog complet respons
pcr tnbc vs chemo alon patient vs
chemo alon encourag use i-spi trial identifi
promis combin evalu phase keytruda chemo combo
first combin emerg test phase
early-stag tnbc merck state plan file keytruda neoadjuv tnbc
year-end base phase test
keytruda chemo vs placebo chemo neoadjuvant/adjuv stage i-iii tnbc
regardless statu adjuv phase patient receiv keytruda
monotherapi chemo co-primari endpoint patholog complet respons pcr
event-fre surviv ef initi data present median follow-
month signific improv pcr rate observ
keytruda chemo vs control overal vs patient vs
patient vv favor trend ef alreadi
emerg hr ci although data immatur
event experienc event-fre surviv ef continu monitor
primari complet estim data like earn keytruda
approv neoadjuv tnbc offer earli sign efficaci import
adjuv set although evid need move keytruda
preval breast cancer histolog tnbc data impress garner
quit bit enthusiasm within breast cancer commun word one
kol peopl go go earli look ef anticip
like boost uptak upon approv data also invit specul
test keytruda chemo metastat tnbc may read posit
data initi expect like earli perhap all-com
would repres real competit threat roch tecentriq
inhibitor current approv tnbc seen robust uptak despit
indic patient
multipl myeloma merck present updat phase data
pembrolizumab combin lenalidomid low dose dexamethason r/r
mm studi enrol heavili pre-treat patient popul
patient receiv prior line patient evalu efficaci
experienc complet respons experienc good partial respons
partial respons orr merck also present phase ii
data combin pomalidomid dexamethason r/r mm
patient evalu efficaci experienc stringent complet respons near
complet respons good partial respons partial respons
encourag signal merck initi phase
combo pom/dex combo len/dex keynote-
howev june base recommend data monitor committe
merck paus enrol trial collect
inform better understand report death unquantifi trial juli
fda place clinic hold
keytruda/ lenalidomide/dexamethason cohort phase
mesothelioma merck present updat phase ib data
mesothelioma mesothelioma cancer line lung
estim mesothelioma patient evalu
efficaci partial respons stabl diseas report orr
dcr consist keytruda studi treatment
discontinu death report plan filing/pivot studi
initi unclear variou investigator-initi trial remain on-going
merkel cell carcinoma merkel cell carcinoma rare aggress skin cancer
 incid cases/year data investigator-initi
phase ii trial show respons rate front line patient treat
keytruda respons uncommon current soc
platinum agent durabl respons appear substanti longer respons
platinum agent usual transient histor mpf month keytruda
deliv mpf month respons current on-going fda
grant keytruda orphan drug design mcc decemb
june present result phase ii trial merkel
cell carcinoma patient posit merkel cell polyomaviru
mcpyv orr mcpyv patient orr mcpyv- patient
overal orr patient follow-up cr pr
neither median median os reach interim analysi
howev surviv keytruda monotherapi result
favor vs histor os rate chemotherapi decemb
keytruda approv merkel cell acceler approv base
merkel cell carcinoma current lead approv
receiv march
endometri juli combin keytruda lenvima eisai receiv btd
advanced/metastat non-msi-h/pmmr endometri carcinoma acceler
approv grant septemb base phase ib/ii
patient metastat endometri carcinoma enrol
includ non-msi-h dmmr tumor week patient
irrespect molecular statu combin demonstr orr ci
data cutoff median follow-up month overal orr
ci complet respons rate median dor
month rang month
pembrolizumab activ patient brain met data suggest
pembrolizumab activ eighteen patient nsclc untreat brain
metastasi treat pembrolizumab patient show either brain
metastasi respons system respons patient system respons also
brain metastasi respons expect one patient transient respons
follow progress importantli respons appear durabl
confirm respons on-going time data analysi neurolog
observ includ headach dizzi cognit dysfunct stroke
grade first evid io activ nsclc
discuss present note respons rate observ studi par
activ melanoma brain metastas panelist also note
activ unlik due pembrolizumab penetr given pembrolizumab
mw time greater chemotherapi time greater tki
water-solubl respons observ like due activ lymphocyt
traffick brain via choroid plexu glial limit membran view data
anoth demonstr io activ late stage diseas believ io may
patient repres altern radiat invas intracrani surgeri
ablynx partnership develop nanobodi antibodi south american
llama develop variou type checkpoint inhibitor
collabor expand merck select addit nanobodi program
aim develop bi- tri-specif antibodi engag multipl target
advaxi collabor evalu pembrolizumab adxs-psa lm-llo
immunotherapi agent target antigen phase i/ii trial
previous treat mcrpc patient initi april interim data
present compar adxs-psa alon combin
keytruda evalu patient receiv adxs-psa monotherapi
achiev progression-fre surviv mo month monotherapi
patient achiev declin though achiev greater-than declin
evalu patient receiv keytruda adxs-psa combin therapi
achiev progression-fre surviv mo reach month
follow-up combin therapi patient achiev declin
remain unclear combin synergist major benefit
carri keytruda interim data phase ii also present
keytruda monotherapi docetaxel-refractori mcrpc patient
overal dcr all-com would appear account increas
progression-fre surviv administ combin adxs-psa addit
compar data analysi need make definit determin
affim januari merck announc collabor evalu affim
nk-cell engag keytruda r/r hodgkin lymphoma bispecif
antibodi bind nk-cell via secondari bind domain
conduct fund phase ib studi evalu
earli interim data present eha patient
treat highest dose mg/kg combin keytruda achiev
best orr complet metabol respons rate
studi remain on-going collabor may expand includ phase
agenu partnership develop two merck immun checkpoint agent use
amgen phase i/ii studi pembrolizumab oncolyt immunotherapi
talimogen laherparepvec imlyg untreat advanc melanoma earli phase ib
data phase ib/iii unresect stage iiib-iv
melanoma present evalu patient keytruda imlyg
combo achiev confirm orr confirm cr median time
respons week upon trial-expans phase enrol
 increas patient trial
estim primari complet juli assess os co-primari
addit collabor expand scchn
keytruda imlyg combin studi phase trial
initi april patient enrol
orr diseas control rate although result
appear substanti improv keytruda monotherapi follow-up on-going
os
array may merck announc clinic collabor array biopharma
evalu binimetinib mek inhibitor keytruda mcrc patient microsatellit
stabl mss tumor phase trial initi decemb
intend enrol patient evalu dose-limit toxic primari endpoint
estim primari complet novemb accord array
incid mss nearli earli stage resect colorect tumor
approxim advanc metastat tumor futur collabor
unknown pend acquisit array close
biolinerx januari merck enter collabor biolinerx
evalu antagonist keytruda phase ii combat
trial metastat pancreat adenocarcinoma juli
collabor expand includ arm keytruda chemo
pancreat cancer biolinerx provid updat octob esmo
total patient treat keytruda evalu dcr
patient stabl diseas mo total popul
month surviv rate patient howev mo increas
month surviv rate result appear favor
compar current approv treatment metastat pancreat
adenocarcinoma chemo combo onivyd leucovorin mo
dynavax june merck announc collabor evalu dynavax
toll-lik receptor agonist combin keytruda
phase ib/ii studi keytruda advanc melanoma
initi septemb data review phase studi
advanc solid hematolog malign also initi
may dynavax announc de-priorit io asset
anticip develop keytruda combin
notic data gener date outlin
octob dynavax provid updat phase ib/ii trial combin
keytruda advanc melanoma inhibitor nave melanoma
patient combin keytruda result orr
demonstr clear durabl orr present
combin keytruda nave melanoma patient result
orr vs orr patient refractori
melanoma treat keytruda treatment result
orr cr appear increas orr melanoma
compar orr orr although previou
result present rang dose patient nave previou
round system therapi orr patient treat
keytruda slightli orr patient present
find naiv melanoma data particularli encourag given high
respons rate observ keytruda monotherapi produc pivot
trial perhap import respons rate keytruda stay
present despit fact number patient
evalu respons dose increas consist
analys suggest real biolog activ melanoma physician
consult said combin produc respons rate least
would reason believ contribut efficaci
find difficult deriv much confid single-arm phase ii trial believ
phase trial clearli warrant nave melanoma
 experienc melanoma respons rate also higher
keytruda monotherapi produc popul nonetheless differ
observ respons rate keytruda monotherapi would
expect produc boil two three addit patient respond given
rel small size trial longer larger studi necessari
confid role indic
eisai march merck announc expand collabor eisai
compani jointli develop commerci lenvima lenvatinib mesyl
monotherapi combin keytruda multipl cancer type eisai book
lenvima sale global monotherapi combin merck eisai
share gross profit equal lenvima current approv thyroid cancer rcc
w/everolimu august approv eu
review japan
keytruda lenvima combin studi rcc nsclc bladder
melanoma well basket trial target multipl tumor type includ
endometri cancer combin earn first approv endometri
cancer septemb
evelo novemb merck announc collabor
evalu keytruda oral monoclon microbi design
engag immun cell small intestin promot chang system biolog
preclin model shown stimul upregul immun
respons tumor combin phase i/ii breast cancer
phase iia advanc melanoma
glaxo novemb phase trial glaxo
initi monotherapi combo pembrolizumab advanc
recurr metastat solid tumor studi estim enrol
patient evalu safeti dlt primari endpoint secondari
endpoint includ orr dcr dor os estim primari complet
februari merck announc collabor
evalu keytruda mirvetuximab soravtansin fr-posit folat receptor
alpha ovarian cancer keytruda ad on-going phase i/ii
forward ii trial evalu mirvetuximab variou combin fr ovarian
cancer march initi phase ib data present show
combin provid modest efficaci benefit vs mirvetuximab monotherapi
octob present data expans cohort phase i/ii
forward ii total patient least baselin scan
demonstr shrinkag target lesion confirm orr pr
mpf month mdor month medium-to-high
fr patient confirm orr mpf month mdor
month describ mild-to-moder grade consist
safeti profil agent safeti efficaci look promis
follow-up need guid clinic develop combin
incyt pembrolizumab epacadostat inhibitor
evalu variou tumor april announc phase
fail melanoma brought collabor near halt
fail despit previou encourag phase i/ii single-arm orr
result combin pembrolizumab epacadostat melanoma well
sever tumor type test pembrolizumab /- epacadostat io-
naiv metastat melanoma patient final analysi combin
demonstr hazard ratio hr os os event
base upon analysi dsmb recommend trial continu final
os analysi report conduct full biomark analys ido
tmb etc extent subset identifi manag partner may
seek modifi design remain random phase trial patient
studi trial incorpor learn altern curtail futur
invest manag believ one potenti modif would shrink size
trial turn pilot random phase ii/iii trial light hr
observ overal popul manag believ difficult identifi
clear subgroup deriv benefit combin
lilli merck enter collabor evalu keytruda combin alimta
cyramza portazza abemaciclib collabor includ phase studi
keytruda alimta non-squam nsclc standard care see
phase ii studi keytruda alimta nsclc phase i/ii
studi keytruda cyramza across multipl tumor type phase i/ii studi
keytruda portrazza across multipl tumor type phase studi
june merck announc collabor therapeut
develop commerci mrna-bas person cancer vaccin pcv merck
paid up-front may pay addit mileston post proof-of-
concept studi novemb phase trial initi
evalu pcv alon keytruda patient solid tumor
may collabor expand includ kra pcv merck
respons clinic develop respons clinic
suppli follow poc studi merck may opt-in develop updat
agreement also allow addit pcv collabor merck made
invest
novarti evalu pembrolizumab pazopanib votrient multi-tki vegfr
pdgfr c-kit advanc rcc underway phase i/ii evalu
combin assess co-primari endpoint primari
complet februari data yet releas
discoveri compani focus cancer immunotherapi compound pre-
clinic pipelin includ ido tdo ido/tdo combo inhibitor financi term
disclos
oncosec medic juli merck expand collabor oncosec
evalu keytruda tavokinogen telseplasmid tavo tnbc patient inoper
local advanc metastat diseas phase ii trial initi
novemb phase ii trial advanc melanoma
keytruda tavo also on-going primari complet octob
intratumor mab sever phase i/ii trial mono combo therapi
decemb press releas oncosec provid initi updat phase ii
advanc melanoma first patient complet week
treatment reach initi tumor evalu patient confirm partial
respons case respons durat reach month one pr
elev cr investig assess evalu enrol
continu await data
partnership initi start phase i/ii studi pembrolizumab
pfizer inlyta small molecul kinas inhibitor rcc pembrolizumab pf-
immunotherapi agent target receptor multipl cancer
type underway phase data present pembro solid
tumor report respons rate refractori popul combo well
toler data support evalu keytruda inlyta earn rcc approv
base impress result describ keytruda also
phase trial combin pfe xtandi mcrpc
plexxikon daiichi sankyo group may merck announc collabor
evalu keytruda pexidartinib plexxikon oral small molecul
inhibitor phase i/ii studi combo advanc melanoma solid tumor
initi june
rexahn pharma august merck establish collabor rexahn
evalu keytruda supinoxin tnbc oral phosphorylated-
inhibitor rexahn sponsor phase ii trial yet start phase
i/ii studi monotherapi tnbc on-going
seattl genet decemb announc initi collabor
enfortumab vedotin would test combin
keytruda metastat bladder cancer lead phase trial
begin
syndax march collabor announc evalu
pembrolizumab entinostat oral small-molecul hdac histon deacetylas
inhibitor shown reduc number function host immun
suppressor cell phase ib/ii studi nsclc melanoma encore-
entinostat current phase hr bc breakthrough
design indic march syndax announc melanoma
cohort reach pre-specifi criteria advanc second stage trial
april trial expand includ arm evalu combo patient
microsatellit stabl base june updat syndax announc
identifi potenti registr pathway patient nsclc progress
inhibitor pivot phase trial keytruda entinostat
nsclc announc yet begun enrol
establish collabor otsuka subsidiari base primarili around
small molecul inhibitor oncogen kra collabor includ preclin
candid merck fund commerci product global taiho
retain co-commerci right japan
tesaro may merck announc collabor evalu tesaro zejula
niraparib parp inhibitor plu keytruda phase i/ii trial tnbc and/or ovarian
cancer phase i/ii topacio trial start march
primari complet march assess orr dose-limit toxic trial
complet futur merck develop focu lynparza
topacio trial present present
time data cutoff ovarian cancer patient evalu initi
respons assess ovarian cancer patient treat median
prior line therapi rang platinum-resist ovarian cancer
platinum-refractori receiv prior bevacizumab platinum
inelig combo report orr assess cr pr sd
dcr evalu popul brcamut cohort orr
dcr brcawt cohort orr dcr hrd
patient orr dcr hrd- patient orr dcr
respons rate depend biomark statu platinum statu
orr platinum-resist ovarian cancer patient platinum-refractori
patient patient platinum inelig median dor
month patient remain treatment common grade
includ anemia thrombocytopenia
topacio also includ tnbc patient
deleteri brca mutat evalu tnbc patient treat
median prior line therapi rang receiv prior platinum
therapi metastat set receiv prior neoadjuvant/adjuv therapi
evalu popul combo report orr dcr
includ pr sd progress diseas
brcamut patient achiev orr dcr includ cr pr
sd progress diseas mpf month ci
grade trae occur patient thrombocytopenia anemia
common
tetralog april collabor announc evalu
pembrolizumab birinap birinap smac-mimet phase studi
relapsed/refractori solid tumor studi estim enrol
patient estim primari complet june base orr safeti
co-primari endpoint earli data present esmo octob report
evalu patient confirm pr combin treatment
safeti profil consist independ administr drug smac-
mimet believ enhanc effect immune-oncolog agent
viralyt june merck complet acquisit australia-bas viralyt
cash-per-share total valu lead candid cavatak
oncolyt immunotherapi base proprietari formul oncolyt viru
coxsackieviru type shown preferenti infect kill cancer
cell cavatak phase i/ii trial intratumor intraven agent
combo keytruda melanoma prostat lung bladder cancer
april merck complet acquisit immun design per share
approxim merck gain access imdz cancer
vaccin current develop combin keytruda overal field
immuno-vaccin rel drug develop believ merck
saw opportun potenti differenti keytruda via combo
august merck establish collabor immun design evalu
keytruda phase trial agonist nhl anti
melanoma off-the-shelf therapi requir ex vivo
manipul activ immun system induction/expans anti-
tumor cell initi data keytruda follicular lymphoma
present june report data evalu patient
monotherapi demonstr partial respons patient
stabl diseas diseas control rate report patient
demonstr shrinkag untreat distal lesion provid anoth updat
decemb includ data well
monotherapi combo escal cohort despit patient enrol
studi disclos number evalu patient arm orr
arm versu monotherapi arm orr
escal cohort patient demonstr
shrinkag untreat tumor appear implicitli better
monotherapi escal cohort orr patient demonstr
shrinkag untreat tumor howev full statist analysi provid
march immun design announc updat data trial
patient monotherapi achiev orr tumor shrinkag
convers patient treat achiev orr
tumor shrinkag latest data suggest object respons
combin therapi improv time furthermor patient high
express demonstr orr increas last interim
analysi combin appear promis immun design
provid updat regard clinic advanc
decemb imdz present long term follow-up data
random phase ii portion combin pembrolizumab follicular
lymphoma fl patient patient receiv two dose local low dose radiat
 follow mcg intratumor peritumor dose
qw schedul patient pembro arm receiv pembro mg begin
day initi radiat new data report show pr
orr combin arm also compar favor orr
arm orr previous diseas control shown
patient treat regimen without pembrolizumab respect
similar trend observ reduct tumor burden distal noninject lesion
abscop respons combin arm exhibit distal tumor reduct
rate distal tumor reduct median also favor
combin arm vs month remain previous
report treatment regimen remain well-toler mainli low-grad
inject site reaction nausea diarrhea asthenia one grade ae
report consid sae combo patient grade coliti adren
insuffici hyponatremia hypocalcemia taken togeth combin
appear highli toler regimen
merck announc may plan acquir clinic stage oncolog
compani peloton therapeut up-front plu addit
conting mileston payment peloton lead asset oral inhibitor
phase ii combin cabozantinib rcc gbm transcript
factor involv cellular respons hypoxia upregul variou
cancer promot oncogen cell surviv de-differenti angiogenesi
although singl agent anti-tumor activ phase rcc monotherapi trial
initi like drug trial combin keytruda well
june merck announc plan acquir anoth immune-
oncolog compani total deal worth tilo privat held preclin
biotech develop antibodi latency-associ peptid lap molecul
promot activ inhibitori immun cell tumor microenviron partli
modifi tgf signal block tgf pathway promot tumor
immunogen strategi explor multipl io-focus compani
primarili combin checkpoint inhibitor acquisit offer merck
intern develop path anoth keytruda-bas io/io combin
januari merck acquir arqul clinic stage biopharma per share
cash equiti valu arqul focus kinas inhibitor discoveri earli data
lead candid arq oral bruton tyrosin kinas btk inhibitor
treatment b-cell malign present phase
enrol r/r cll/sll wm b-cell nhl patient total cll/sll b-
cell nhl prior line therapi patient progress btki
cll/sll patient harbor btk resist mutat
patient receiv arq daili dose use
cohort expans across dose malign pr rate
addit experienc stabl diseas orr evalu cll
patient btk cll/sll patient receiv dose patient
experienc pr tumor reduct greater identifi
grade trae includ rash neutropenia decreas platelet
arq stellar earli efficaci profil current good better close
competitor long-term follow-up larger sampl size ibrutinib-
resist cll patient requir better assess competit dynam regardless
arq well posit address larg unmet need
januari merck bristol/ono announc global licens agreement
settl patent infring litig relat use cancer treatment
agreement dismiss prejudic patent litig pertain keytruda part
agreement merck made initi payment record
bristol/ono record merck also pay royalti global keytruda
sale
royalti split bristol ono compani
also grant certain right respect patent portfolio
pertain
juli merck announc oncolog collabor astrazeneca co-
develop co-commerci parp inhibitor lynparza mek inhibitor
selumetinib collabor includ mono combo therapi although
compani independ develop lynparza selumetinib combin
respect agent merck paid astra up-front
licens option regulatori one-third sale two-third
merck cite interest dna repair fact lynparza advanc
parp trial time reason found deal astra attract merck
view non-exclusivity/lack tumor carve-out deal risk given
hard anticip ideal combin futur merck
record lynparza/selumetinib sale net commerci cost retain
keytruda sale merck share develop cost record total
 estim revenu collabor lynparza selumetinib
lynparza oral inhibitor poly-adp-ribos polymeras
parp enzym involv dna repair brca mutat cancer increas
relianc parp repair dna continu divid parp inhibitor
shown impress efficaci brca mutat cancer tumor homolog
recombin repair defici hrd also shown respons parp
inhibit data suggest agent found clinic relev beyond
brca hrd especi combin mechan ddr inhibitor io
anti-angiogen agent akt inhibitor etc lynparza approv ovarian us
eu japan china breast us eu pancreat cancer us
approv prostat cancer ovarian mainten cancer expect
pdufa studi gastric cancer fail show benefit
complet discuss lynparza data see astrazeneca section
januvia once-daili inhibitor domin posit market
ww share
januvia strong posit within class due sizeabl time advantag
launch year ahead competitor strong commerci execut
combin twice-daili metformin janumet xr janumet avail
major market combin steglatro ertugliflozin roll
warn precaut section label includ risk pancreat renal failur
allerg reaction includ stevens-johnson arthralgia januvia almost entir
excret renal requir downward dose-adjust patient ckd mg
moder ckd mg sever ckd two-tier adjust rel
disadvantag versu onglyza requir one downward adjust howev
januvia inhibit offer limit drug-drug interact patent
expir eu juli pedi exclus could add anoth
month forecast januvia/janumet sale
data teco larg phase studi enrol patient
establish cardiovascular diseas present ada data show
ad januvia current standard care increas risk major cv event
kaplan-mei curv almost perfectli superimpos hr
primari endpoint cv death mi stroke hospit unstabl angina
secondari endpoint cv death mi stroke
studi also show long-term pancreat risk pancreat cancer numer
higher placebo acut pancreat common januvia differ
statist signific importantli teco show increas risk
hf-hospit onglyza azn show statist
significantli higher risk nesina takeda unfavor trend
increas risk reflect label drug
januvia lack hf signal vs may reflect intrins pharmacolog
differ drug differ patient enrol background therapi
definit hf event trial design dynam
howev april merck receiv fda teco data
kol think fda may request specif data studi peopl
preexist hf grant januvia new label
august fda issu warn drug may caus sever
disabl joint pain arthralgia signal current reflect label across
class complex manag occur sometim immedi
time year fda note symptom usual ceas within month post
march public butler et al diabet specul glp-
may associ increas incid pancreat duct metaplasia patient
studi suffici control determin causal relationship
fda releas safeti commun respons find
howev evid prospect design studi report
reassur increas risk pancreat cancer report outcom
studi report date enrol total patient tabl
current label reflect risk pancreat pancreat cancer
marizev once-weekli dpp-iv inhibitor offer
conveni may day merck show data suggest
curv marizev januvia virtual superimpos drug approv
japan base o-qwest studi seri phase studi compar
marizev januvia enrol patient studi met primari endpoint
non-inferior reduct week meaning differ side
effect vs januvia report except risk nasopharyng vs
placebo januvia like januvia marizev gener weight neutral non-
increas risk hypoglycemia report
merck receiv approv omarigliptin japan septemb file us
expect announc discontinu clinic develop
compani cite cannib januvia market share focu
primari reason support decis note decis
result concern safeti efficaci estim marizev sale
merck enter collabor develop
commerci steglatro includ potenti fixed-
dose combin januvia metformin receiv up-front
elig addit mileston payment merck share revenu
certain cost basi
first phase announc ada primari endpoint met trial
verti mono trial ertugliflozin monotherapi
demonstr reduct respect vs placebo
also ertugliflozin patient attain
vs placebo verti factori trial
ertugliflozin januvia demonstr reduct
ertugliflozin sitagliptin vs ertugliflozin
alon ertugliflozin alon sitagliptin alon
addit ertugliflozin januvia patient attain
steglatro approv decemb along steglujan fdc
ertugliflozin plu sitagliptin januvia segluromet fdc ertugliflozin
plu metformin eu approv grant april forecast steglatro sale
merck/pfiz initi long-term cv studi verti cv ertugliflozin novemb
target enrol patient complet
establish vascular diseas primari endpoint non-inferior vs placebo
composit cv death non-fat mi non-fat stroke pre-specifi secondari
endpoint ad test superior composit cv death
hospit hf superior cv death alon primari complet
decemb data present yet
februari merck enter multi-year collabor privately-held
biotherapeut develop commerci agent area diabet
metabol dysregul malign merck option licens result
program follow human poc studi lead program current
phase ii nash includ collabor merck paid up-front
acquir equiti stake commit
fund initi five-year term collabor
januari merck exercis option licens mab
agonist receptor complex evalu nash
advanc phase ii march merck/ngm collabor
extend two year merck continu fund effort
similar level origin term merck also announc termin licens
return right receptor agonist program obes effect may
juli merck acquir privat held lead
antagonist merck paid up-front cash acquir affer may pay
potenti mileston payment receptor famili ligand-
gate ion channel activ presenc extracellular atp addit
serv neurotransmitt pain tast pathway tissu injuri inflamm
lead increas level atp releas drive receptor hyperact human
type receptor differ role expression-pattern
throughout bodi receptor drug develop current focus
gefapix current evalu chronic acut
cough endometriosi ipf sleep apnea migrain estim gefapix sale
indic
may merck report data phase ii studi chronic cough
highest dose studi reduc awak cough frequenc coughs/hour
primari endpoint week baselin compar placebo lower dose
show statist signific reduct
common alter tast effect call dysgeusia
hypogeusia alter tast describ kol flat tasteless effect
aris gefapix block heterotrimer receptor addit
homotrimer receptor oral sensori neuron taste-a
discontinu group discontinu lower dose
on-going phase chronic cough trial gefapix gefapix
vs placebo primari complet
gefapix vs placebo primari complet
coughs/hour studi complet percent patient experienc least ae
percent patient discontinu treatment due fda appar
establish cough trial endpoint endpoint util contemporari cough trial
includ measur chang cough rate via cough monitor incorpor qualiti
life metric object cough-count ad quantit rigor beyond patient-
previou trial shown wide rang cough reduct trial
high-dos gefapix bid demonstr cough reduct
treatment arm cough reduct placebo arm treatment effect
cough reduct hasnt alway associ improv qualiti
life given high incid side effect trial gefapix studi publish
show treat patient develop dysgeusia alter tast
end on-going chronic cough trial trial incorpor qol
measur determin net benefit
gefapix dose kol conjectur reduct
hour coughs/hour still could achiev similar high-dos studi due part
longer trial kol believ cough trial short patient
perceiv improv cough particularli sinc patient tend improv
time cough beget cough presum revers also true chronic cough
trial least week patient realiz true chang cough
reduct qol improv inhibit receptor desensit
time may allow efficaci lower dose howev risk trial
long patient could develop cold influenza upper respiratori infect
associ cough kol also propon cross-ov
patient serv control better gaug chang cough incid
gefapix trial incorpor cross-ov phase trial
dysgeusia make design phase trial challeng given
approv treatment cough except dextromethorphan chronic cough trial requir
particip addit agent associ cough trial
also requir subject start new agent proton-pump inhibitor ace
inhibitor sinu treatment trial
normal tast percept tast bud releas atp bind receptor
sensori neuron tongu mouth transmit signal
block interact atp receptor lead alter tast
underli mechan dysgeusia describ kol flat tasteless
effect oral sensori neuron contain mixtur homotrimer
heterotrimer receptor clear form need block
drive efficaci cough howev block heterom believ
respons dysgeusia
reduc dysgeusia effect trial lower dose bid
bid extend treatment period slow cough-reduct without
elicit tasteless effect ask dysgeusia ae rel
select competit note competit data limit
side effect reduc phase ii lower-dos gefapix
patient receiv comment
phase ii discontinu due tast unmet need
treatment idiopath chronic cough would like overrid discontinu due
kol believ dysgeusia potenti could avoid
select would challeng exclus target homom
composit heterom receptor well understood make
synthesi select agent real challeng howev sever compani bellu
bayer shionogi state done kol conjectur
compound greater receptor-select could found high-
gefapix success phase subsequ file chronic cough
like would review fda pulmonary-allergi drug advisori committe
kol believ pulmonari divis would keen review new drug chronic
cough patient advocaci also could play role review process approv
kol believ patient would call immedi start treatment
chronic cough debilit remaind patient like would start
treatment next visit base physician recommend minim seriou
advers event profil would facilit adopt
endometriosi type inflammatori pain also heighten receptor activ
pain associ endometriosi may treat non-steroid anti-
inflammatori agent target inflam tissu preclin model
inflammatori pain nerv injuri arthriti gefapix reliev pain similar
level anti-inflammatori dose would equival gefapix
dose use human kol expect gefapix show signific pain-reduct
effect migrain mechanist similar endometriosi migrain headach
origin stimul sensori nerv mening known
preclin human studi highli express cranial sensori nerv
cytokin releas migrain caus hypersensit receptor
base mechan inhibitor could also util migrain data
need confirm
idiopath pulmonari fibrosi ipf anoth potenti indic
patient chronic cough number coughs/hour similar chronic cough
coughs/ hour ipf present men year old oppos idiopath chronic
cough present middle-ag women small ipf trial
administ inhibitor bid found reduct cough result
show reduct drug group vs reduct placebo
group effect found statist signific drug well-
toler dysgeusia common ae treatment group kol
conjectur mainli treat cough ipf remain unclear
cough caus ipf ipf caus cough kol know trial seek
use therapi ipf
addit sale consum busi merck also enter
development/market collabor bayer cardiovascular health merck earli
stage compound area also part ventur merck made up-front
payment bayer may respons futur mileston payment
collabor includ bayer portfolio solubl guanyl cyclas sgc modul
includ adempa riociguat approv pah cteph
japan cteph vericiguat
vericiguat oral sgc stimul develop add-on therapi
treatment reduc eject fraction heart failur hfref phase victoria trial
placebo-control trial enrol patient patient enrol
despit optim therapi still symptom primari endpoint time first
occurr composit endpoint cv death hf hospit
number secondari endpoint total follow time year septemb
merck announc vericiguat met primari endpoint full data
present futur medic meet
cowen confer septemb specialist anticip
posit result victoria wherea investor share optim
even among specialist kol panelist concern voic
addit vericiguat soc patient alreadi optim treatment would leav
room larg enough delta garner posit result vericiguat appear
pass hurdl commerci potenti depend data mainli
much risk reduct seen potenti indic associ
pulmonari arteri pressur alter note august meet
manag specif offer
estim vericiguat sale
remicad infliximab chimer anti-tnf monoclon antibodi approv
treatment ra sign symptom inhibit diseas radiograph
progress ankylos spondyl psoriasi psoriat arthriti crohn diseas
acut mainten use fistula closur prevent ulcer coliti merck
market remicad ex-u market remicad sale europ increas
substanti year driven new indic broader market
howev biosimilar launch quit success smaller
market remicad face tough brand competitor larger market mid-
celltrion receiv approv biosimilar infliximab six indic
remicad patent began expir market remaind
 patent expir februari remicad approxim market share
unit ye reflect biosimilar impact
remicad sale forecast ex
octob approv simponi treatment adult ra psoriat
arthriti ankylos spondyl simponi subcutan dose util
smartject auto-injector place level field humira enbrel once-
monthli dose also may advantag competit longer act
agent especi psoriasi includ jnj stelara ustekinumab dose
everi three month simponi efficaci safeti appear robust may fda
approv simponi treatment moder sever activ ulcer coliti
inadequ respons convent therapi approv
gain septemb june simponi receiv approv use non-
radiograph axial spondyloarthr forecast simponi sale ex-u
zepati merck hep oral combo grazoprevir second-gen proteas inhibitor
elbasvir inhibitor approv januari eu juli
hcv genotyp approv genotyp base c-edg tn c-edg
coinfect c-edg te c-salvag c-suffer approv genotyp base
c-edg tn c-edg coinfect c-edg te c-scape zepati launch
japan launch impress howev competit ramp
notabl abbv mavyret zepati sale expect declin
beyond zepati shortcom includ effect fewer genotyp requir
ribavirin longer treatment durat genotyp requir liver test
estim zepati sale
iqvia includ harvoni sovaldi epclusa includ mavyret viekira pak viekira xr includ
isentress raltegravir oral integras inhibitor approv octob use
combin antiretrovir agent treatment infect
treatment-experienc adult patient multi-drug resist dose
bid integras key enzym enabl hiv integr host genom
vital element replic life cycl
isentress approv eu treatment-nav hiv patient
januari fda approv isentress pediatr oral suspens expand use
patient week combin agent februari fda
approv dutrebi fixed-dos combin isentress lamivudin
use combin antiretrovir agent once-daili formul
isentress hd met primari secondari endpoint phase oncemrk
primari endpoint isentress bid raltegravir given
once-daili combin therapi truvada found statist
non-inferior proport patient achiev rna copies/ml week
juli oncemrk data treatment nave hiv patient re-affirmed
safeti efficaci isentress hd daili version approv
may eu juli novemb fda approv isentress
use newborn hiv birth week age weigh least kg
isentress face number competitor includ glaxo unboost integras
inhibitor dolutegravir tivicay approv august treatment-nav
treatment-experienc patient triumeq combo tivicay/epzicom/kivexa approv
august juluca dolutegravir rilpivirin first single-pil daili
approv novemb landscap intensifi approv
gilead biktarvi februari today less clear favorit mani
physician use taf/emtriva tivicay forecast isentress sale
croi data present aid clinic trial group studi
compar twice-daili isentress once-daili ritonavir-boost proteas inhibitor
atazanavir reyataz darunavir prezista larg treatment-nav patient
open-label trial result show high equival efficaci measur
time virolog failur co-primari endpoint three regimen percentag
patient maintain copies/ml week isentress
reyataz prezista base analysi co-primari endpoint
toler failur isentress prezista regimen superior reyataz
percentag patient discontinu treatment toxic reason
isentress reyataz prezista
treatment-nav data switch data present croi
treatment-nav data posit switchmrk studi fail stop
earli juli result show isentress effect efavirenz
maintain viral load suppress undetect level copies/ml
improv count treatment-nav patient week phase ii
medicin administ combin two anti-hiv medicin
tenofovir lamivudin
kol believ switchmrk data indic isentress lower genet barrier
prompt greater caution use first-lin agent combin
potenti fragil phase trial compar daili isentress current
fda-approv dose regimen bid treatment-nav adult infect hiv-
once-daili dose regimen fail meet pre-specifi non-inferior
endpoint patient achiev undetect viral load week
bid treatment group compar dose once-daili differ effect
driven primarili patient high viral load copies/ml hiv-rna
patient achiev suppress twice-daili dose compar
patient receiv isentress day data prompt merck end
studi septemb merck announc result realmrk clinic studi
show week treatment open-label single-arm observ
studi isentress tablet combin therapi demonstr efficaci toler
regardless gender race divers popul adult patient
infect similar result phase studi
highli suit qd fix dose regimen potenc
efavirenz without side effect manag believ import
option outsid integras inhibitor class non-nucleosid revers
transcriptas inhibitor nnrti regimen one commonli use treatment
regimen early-lin patient popul believ doravirin add divers
merck portfolio improv limit nnrti class
neurolog resist
august fda approv doravirin daili tablet pifeltro
administ antiretrovir fdc doravirin lamivudin
tenofovir disoproxil fumar delstrigo treatment hiv adult prior
antiretrovir treatment product label includ box warn post
treatment acut exacerb hbv eu approv product receiv
novemb label updat allow viral suppress patient switch pifeltro
delstrigo fda approv septemb estim doravirin pifeltro
delstrigo sale
doravirin approv base two phase studi drive-ahead drive-
forward phase drive-ahead random control trial evalu
safeti efficaci once-daili doravirin vs once-daili efavirenz atripla gilead
drive-ahead percentag patient rna
copies/ml doravirin statist non-inferior efavirenz
patient high viral load doravirin efavirenz rate
achiev rna copies/ml week group
inferior increas mean t-cell count baselin week
cells/mm doravirin cells/mm efavirenz treatment-emerg viral
mutat caus drug-associ resist doravirin
efavirenz studi also met primari safeti endpoint doravirin result
fewer neuropsychiatr octob present data
found consist
phase drive-forward trial evalu safeti efficaci doravirin
combin antiretrovir agent treatment-nav infect
patient patient random receiv once-daili doravirin once-daili
ritonavir-boost darunavir combin emtricitabin tenofovir
disoproxil fumar ftc/tdf abacavir lamivudin februari
present result demonstr once-daili doravirin met
primari efficaci endpoint non-inferior compar ritonavir-boost darunavir
juli data show proport particip achiev rna
less copies/ml doravirin ritonavir-boost
darunavir mean chang baselin t-cell count
doravirin ritonavir-boost darunavir rate
discontinu due doravirin ritonavir-boost
believ doravirin bridg long-act asset islatravir
precursor deriv tabasco sauc islatravir new class
molecul call nucleosid revers transcriptas transloc inhibitor nrtti
describ high potenc favor resist profil favor
kinet allow flexibl dose allow potenti combin
believ pre-exposur prophylaxi flexibl schedul could allow greater
option either once-daili once-weekli longer implant one
year long half-lif may allow greater forgiv miss dose could
import distinguish featur in-hous phase ii data suggest signific
efficaci combin doravirin expect present upcom
medic meet patent base substanc formul combin
juli present islatravir result phase iib studi ia
part studi week adult patient randomli assign receiv
one three dose islatravir plu doravirin
lamivudin delstrigo compar part achiev undetect
viral load copies/ml three-drug combin drop lamivudin
stay islatravir doravirin two-drug regimen week
week percentag patient hiv rna copies/ml therefor
part elig dose
islatravir respect vs take delstrigo week
peopl take respect islatravir dose maintain viral suppress
delstrigo treatment regard safe well-toler
peopl take islatravir experienc drug-rel none low-dos
cohort vs patient delstrigo seriou uncommon though
patient discontinu treatment high-dos islatravir cohort vs patient
delstrigo result encourag support continu evalu phase
studi yet initi estim islatravir sale
also work suit molecul potenti more-favor
pharmacokinet could allow combin islatravir estim
hiv market grow next year expect doravirin
islatravir make larg impact
target gram-neg infect approv treatment complic
urinari tract infect complic intra-abdomin infect merck highlight
strong point superior uti indic explicit languag activ
extend spectrum beta lactamas produc organ esbl zerbaxa
label includ warn decreas efficaci seen patient renal
impair id expert concern warn given appear
label compound consid patient like
requir treatment resist pathogen limit altern therapi
warn signific obstacl zerbaxa launch price
line brand antibiot octob zerbaxa
approv eu use ciai cuti acut pyelonephr june zerbaxa
approv habp/vabp base aspect-np trial posit
chmp opinion receiv juli forecast zerbaxa sale
septemb merck announc phase aspect-np studi
compar zerbaxa imipenem hospit acquir pneumonia habp ventil
assist bacteri pneumonia vabp met primari endpoint non-inferior
meropenem activ compar day all-caus mortal vs key
secondari endpoint clinic cure rate test-of-cur visit vs
addit analysi also show clinic microbiolog respons rate
zerbaxa meropenem gram neg respiratori pathogen includ
pseudomona aeruginosa enterobacteriacea treatment emerg advers event
report zerbaxa patient vs meropenem
common report zerbaxa abnorm lft difficil coliti
diarrhea full data present eccmid june
result pivot phase studi cuti aspect-cuti publish
lancet april show zerbaxa non-inferior levofloxacin
composit cure rate patient treat zerbaxa compar
patient treat gener levofloxacin
occur ceftolozane-tazobactam
levofloxacin group respect frequent treatment group
headach gi symptom mild moder seriou
occur ceftolozane-tazobactam
levofloxacin group respect editori journal comment zerbaxa
innov treatment option especi multi-drug resist gram-neg
bacteria especi given efficaci coli pneumonia aeruginosa
februari cubist publish data pivot phase trial aspect-ciai
compar zerbaxa metronidazol meropenem hospit patient
complic intra-abdomin infect ciai trial met primari endpoint non-
inferior fda ema primari endpoint clinic cure rate
patient infect esbl-produc enterobacteriacea vs
patient treat zerbaxa meropenem respect per-pathogen
microbiolog erad rate vs coli vs
klebsiella pneumonia vs pseudomona aeruginosa
recarbrio class beta-lactamas inhibitor
evalu combin imipenem/cilastatin treatment
hospital-acquir bacteri pneumonia habp ventilator-associ bacteri
pneumonia vabp preclin studi relebactam administ combin
imipenem/cilastatin demonstr antibacteri activ broad rang gram-
neg beta-lactam-resist pathogen
juli recarbrio approv cuti ciai caus certain gram-
neg bacteria adult patient limit altern treatment option
posit chmp opinion receiv decemb recarbrio also file
habp/vabp pdufa june estim recarbrio sale
phase trial initi restore-imi evalu
relebactam imipenem/cilastatin versu colistimeth imipenem/cilastatin
patient imipenem-resist bacteri infect habp/vabp ciai cuti
includ caus pseudomona aeruginosa kpc-produc organ
piperacillin/tazobactam patient either hospital-acquir ventilator-
april result restore-imi present relebactam
imipenem/cilastatin rel/imi met primari endpoint favor overal respons
defin relev endpoint differ infect type popul
compar colistin imipenem/cilastatin col/imi result
secondari efficaci endpoint also posit favor clinic respons day
rel/imi vs col/imi all-caus mortal
rel/imi vs col/imi importantli safeti profil posit
drug-rel rel/imi vs col/imi treatment-emerg
nephrotox rel/imi vs col/imi
septemb posit top-lin data announc restore-imi
primari key secondari endpoint non-inferior met full data present
eccmid april
sivextro tedizolid second-gener oxazolidinon acquir part
cubist sivextro appear conveni version pfizer zyvox
similarli avail oral iv formul tedizolid bind bacteri
ribosom subunit inhibit mrna translat protein synthesi phase
studi conduct europ region world-wide absssi
demonstr sivextro mg daili day statist non-inferior
zyvox mg twice daili day advers event rate similar
group gastrointestin advers event diarrhea nausea vomit
common june fda approv oral iv formul
sivextro absssi ema approv sivextro march
zyvox sivextro two brand antibiot gram bacteria
oral iv formul allow physician smoothli transit patient
oral upon discharg hospit zyvox dose day sivextro
six day sinc hospit increas pressur shorten hospit time
sivextro shorter durat therapi offer key advantag zyvox
advantag zyvox includ minim interact serotonerg agent possibl
lower advers event associ impair mitochondri protein synthesi
myelosuppress lactic acidosi peripheral/opt neuropathi retent
vitro activ zyvox-resist gram-posit bacteria zyvox basic product
patent expir forecast sivextro sale
april merck gain world-wide right medarex develop
commerci actoxumab/bezlotoxumab human monoclon antibodi
 difficil toxin toxin toxin combin toxin damag gut
wall caus signific inflamm lead symptom difficil enter
includ abdomin pain wateri diarrhea antibodi suppress toxin
allevi symptom cdi clostridium difficil infect
address underli dysbiosi microbiom
phase studi modifi ii initi octob
evalu actoxumab/bezlotoxumab compar individu mab placebo
septemb merck announc primari endpoint cdi recurr
week met trial base result merck file zinplava
bezlotoxumab eu late prevent difficil infect
recurr octob fda approv zinplava use adult receiv
antibacteri treatment cdi high risk cdi recurr merck launch
zinplava februari zinplava receiv eu approv septemb
estim zinplava sale
june fda advisori panel vote one abstent zinplava
show substanti evid safeti efficaci prevent recurr
clostridium difficil infect cdi howev panelist voic concern data
packag specif regard efficaci second phase trial meet
statist signific global cure endpoint modifi
modifi ii rate difficil infect recurr week primari
efficaci endpoint significantli lower zinplava arm
compar placebo arm respect base
pre-phas commun howev fda indic prefer
global cure primari endpoint global cure track modifi defin
proport subject clinic cure baselin cdi episod cdi
recurr week cdi episod defin lack diarrhea
neg difficil test modifi ii trial zinplava superior placebo
although numer differ favor zinplava placebo respect
achiev global cure statist signific attain versu
overal merck saw reduct hospit stay zinplava panelist state
cure rate import note merit recurr data exist larg
unmet need support fact improv recurr
receiv favor panel also signific panel discuss
degre potenti clinic benefit drug zinplava mechan could show
panelist suggest moa downstream specif impact
toxin major impact diseas cours
dificid fidaxomicin acquir cubist first new class antibiot
call macrocycl inhibit bacteri enzym rna polymeras
bactericid effect interf gene transcript narrow-spectrum profil
dificid may erad difficil select result highli differenti product
compar metronidazol vancomycin dificid may facilit return
normal physiolog condit colon reduc probabl cdi
dificid approv fda may treatment cdad adult
patient astella right develop commerci fidaxomicin
europ specifi countri middl east africa merck retain
right fidaxomicin ex-u region merck also develop oral
suspens formul fidaxomicin use intens care unit elderli
patient label updat suspens formul use children age
 approv januari forecast dificid sale
bridion sugammadex first-in-class novel modifi gamma-cyclodextran select
non-depolar neuromuscular blocker revers agent rocuronium vecuronium
neuromuscular block agent use facilit endotrach intub
mechan ventil surgeri sugammadex revers paralysi induc
two drug
juli european commiss approv bridion routin revers
rocuronium vecuronium immedi revers rocuronium adult rout
revers rocuronium children age year decemb bridion
receiv approv launch januari label includ
contraind patient known hypersensit sugammadex risk
anaphylaxi includ warn precaut section label also cite
anaphylaxi occur healthi volunt safeti
efficaci establish patient year age wac price
vial vial bridion launch china
bridion well posit avail class agent indic
acetylcholinesteras inhibitor slow onset effect requir co-
administr muscarin antagonist agent highli variabl time
neuromuscular blockad revers high rate residu blockad
estim bridion sale
august belsomra orexin receptor antagonist
fda approv difficulti fall stay asleep approv four
dosag start dose increas
elderli non-elderli dose effect dose
indic patient inhibitor late august issu final
schedul belsomra class iv drug becam effect day
public belsomra launch januari
price suvorex approv japan launch novemb
compani discuss ema potenti file japan
account sleep agent usag belsomra trend modest sinc launch
merck conduct physician educ dtc advertis boost sale
may merck present posit phase data treatment insomnia patient
mild-to-moder alzheim compani evalu potenti file
next step disclos belsomra sale forecast
orexin antagonist propos offer similar efficaci approv insomnia agent
without mani liabil belsomra shorter half-lif gsk
almorex discontinu januari like due half-lif
glaxosmithklin anoth orexin receptor antagonist collabor
hgsi sleep disord phase ii
april merck present sever addit abstract sleep support
previous present data abstract support profil suvorex
effect sleep enhanc devoid ecg abnorm next-day impair
suvorex improv sever sleep paramet demonstr toler
similar placebo placebo-control safeti efficaci studi
ecg studi patient random suvorex sever hypnot sleep
medic ecg taken non-rem rem sleep day week
suvorex limit effect ecg profil contrast hypnot
third studi elderli subject random zopiclon suvorex eight
consecut night sever measur drive perform measur
next morn suvorex produc clinic meaning chang rel
placebo zopiclon significantli impair patient next-day drive perform
februari merck announc complet phase program suvorex
twelve-month phase data present esr septemb
studi design safeti studi without primari efficaci endpoint suvorex
improv time sleep significantli reduc time awak compar placebo
advers event evenli distribut amongst treatment group
physician expert character phase safeti efficaci data
suvorex robust suvorex expect captur insomnia
market month post launch given superior mechanist specif compar
drug target gaba system share gain driven strong promot
effort merck physician expert believ suvorex take share
lunesta ambien/cr greatest opportun take share
lunesta
merck develop gardasil nine-val hpv vaccin provid broader
coverag hpv origin version hpv antigen type includ gardasil
origin four plu gardasil provid
immun cervic cancer alum use adjuv four phase
safety/ immunogen studi enrol patient met primari
secondari endpoint gardasil vaccin shown provid suffici
immunogen adolesc safe concomit use vaccin adacel
menacra solid immunogen patient previous vaccin
gardasil octob final phase data present show sustain
efficaci six year
decemb gardasil receiv fda approv use girls/women age
boy age administ three separ shot month
month februari gardasil ad recommend list routin
vaccin acip girl boy gardasil vaccin also
recommend femal age male age
previous vaccin complet seri decemb fda
approv gardasil use male year age octob
fda grant label updat expand approv age women men age
gardasil price wac
two-dos regimen month month approv octob
also octob acip support schedul boy girl
age initi hpv vaccin recommend minimum
interv two dose schedul recommend
start vaccin older age immunocompromis patient two-dos
schedul dampen sale compani see transit complet
june acip recommend share clinic decis make vaccin adult
age adequ vaccin also recommend catch-up vaccin
guidelin includ person age femal
gardasil seen strong growth last month due chang public
sentiment vaccin treat hpv reacceler gardasil growth
driven new geographi china gender-neutr immun program
age rang expans especi increas vaccin
meaning declin cervic cancer outcom need valid
chang narr gardasil one cancer vaccin estim
world elig popul receiv hpv vaccin doubl
gardasil manufactur capac recent year expect doubl
time frame provid new capac expect avail two
new bulk manufactur facil ad help meet ou
demand contract manufactur util form/fil bulk purif
bottleneck forecast gardasil sale
gardasil approv eu june juli ema announc
would conduct safeti review hpv vaccin data evalu report
rare seriou side effect complex region pain syndrom postur
orthostat tachycardia syndrom review complet decemb
associ found
june japanes govern withdrew recommend use hpv
vaccin gardasil gsk cervarix girl cite concern public
potenti advers effect vaccin still avail use
promot studi done evalu alleg advers effect includ pain
joint pain convuls merck work govern obtain/verifi
necessari safeti data recommend reinstat japanes sale
gardasil decis announc roughli
time cdc report hpv vaccin underutil effort
made encourag immun especi girl age juli
govern brazil announc would includ hpv vaccin health
may gardasil receiv approv china launch novemb
open potenti larg new market cervic cancer second common
cancer women age breast cancer china gsk cervarix also recent
receiv chines approv market competit although gardasil provid
broader hpv coverag suppli constraint hamper ou sale
compani indic challeng keep increas demand due
fill-finish rather api merck grown product volum capac sinc
continu make step-chang increas capac deliv growth gardasil base
higher demand
shingl pain remind person chickenpox child varicella-
zoster viru vzv remain dormant linger nerv adjac spinal cord
skull decad circumst immun suppress stress
viru reactiv travel nerv reach skin caus blister
rash inflamm sever case shingl also caus pain
neuropathi spread facial cranial nerv lead hear
vision loss incid shingl estim rise sharpli age incid
rate per peopl per year
year age respect
zostavax singl high-dos live attenu varicella vaccin approv fda
adult year old label expand includ adult
year old although date cdc recommend vaccin year old
zostavax price singl subcutan dose howev zostavax
lead posit overtaken gsk shingrix schedul
approv octob garner preferenti recommend
immun patient age older zostavax recommend age
older peopl previous receiv zostavax prefer
vaccin herp zoster immun shingrix approv eu japan
march estim zostavax sale
pneumococc conjug vaccin eleven phase trial first
initi april data expect consist pneumococc
polysaccharid serotyp conjug carrier protein longer-
term believ polysaccharid librari conjug capabl enabl
tailor uniqu vaccin differ market segment highlight strategi
investor day june unveil pneumococc vaccin
specif design target epidemiolog adult popul manag
comment similar effort underway creat uniqu offer
januari fda grant breakthrough therapi design may
posit phase ii data trial healthi infant report
show noninferior share serotyp immun
respons two addit serotyp safeti profil
compar base result survey
kol expect prefer choic adult children potenti launch
time unclear due ip believ conjug vaccin
also phase month behind even launch first pfizer
would close enough behind acip would unlik render definit
recommend vaccin provid coverag preval strain
cover cover risk valent product could
overwhelm immun system lead interfer therefor diminish efficaci
reason develop vaccin combin
would gener coverag estim sale
pneumococc market largest vaccin market global expect
grow next decad unmet need includ serotyp
cover today vaccin also need higher immunogen
particular valent pediatr segment make pcv market
global immun program still death annual next-gen
candid aim target residu diseas children adult global
immun program creat signific burden pneumococc diseas
hospitalizations/year next-gener vaccin
expect add breadth current portfolio treat adult
rotateq oral liquid pentaval bovin reassort vaccin
market prevent rotaviru diseas prompt sever diarrhea
infant acip recommend rotateq routin immun infant start
week age dose administ week interv
dose rotateq includ vaccin children program
safeti trial patient rotateq demonstr efficaci sever
rotaviru gastroenter rge efficaci rge sever
european subset larg clinic studi rest rotaviru efficaci safeti
trial rotateq demonstr clinic efficaci sever rotaviru diseas
first rotaviru season vaccin efficaci remain high two
rotaviru season follow prevent sever rotaviru case rest
sub-analysi rotateq reduc number hospit emerg
depart visit due serotyp number gp surgeri
visit two year post vaccin europ intussuscept type
bowel blockag potenti side effect rotaviru vaccin june
meet acip advisori committe immun practic review new data
show increas risk intussuscept receiv gsk rotarix
lesser degre rotateq incid rang extra case per
children receiv vaccin howev data also show mark decreas
hospit death due rotaviru acip believ far outweigh
decemb rotateq label updat includ data demonstr
reduct hospit emerg visit caus rotaviru
serotyp septemb rotateq label updat includ pertussi immun
respons data rest support concomit use dtap rotateq rotateq
first-mov advantag penetr birth cohort posit
well competit glaxosmithklin rotarix approv fda
april recommend acip june howev rotarix human
monoval vaccin potenti potent requir two vaccin
versu rotateq three vaccin consult highlight sinc introduct
rotateq rotaviru infect drop despit infant
receiv one dose rotateq implic unclear given
scientif data support efficaci singl dose rotateq approv china
april forecast rotateq sale
novemb merck enter exclus licens collabor
agreement newlink genet nlnk develop manufactur distribut
newlink investig rvsv-zebov-gp ebola vaccin ervebo
use part specif protocol protect peopl high risk infect
healthcar worker expos infect patient commerci approv
eu novemb decemb estim ervebo sale
studi support approv includ prevail phase ii/iii studi
liberia/oth west african countri enrol approxim healthi
adult phase studi guinea conduct local agenc
strive phase ii/iii studi evalu health care frontlin
worker sierra leon led local agenc cdc juli ebola
vaccin receiv breakthrough therapi design prime prioriti
medicin statu eu
juli data interim analysi phase trial guinea show
efficaci ci follow singl vaccin dose
individu protect ebola viru within day vaccin editori
journal note despit variou limit studi data call
widespread use vaccin outbreak
may merck announc dose ship use
ebola outbreak democrat republ congo second shipment
area dose sent august hhs/barda announc
fund addit year manufactur
dengu remain signific health concern mani part world lead
hemorrhag fever mortal dengu infect annual
patient risk world-wide investor day june highlight
in-licens dengu vaccin partnership instituto butantan brazil
phase data suggest vaccin broad antigen coverag protect
dengu serotyp import partial protect thought
associ advers outcom presum refer sni dengvaxia phase
trial current underway instituto butantan manag eye public
 dose dose week dose week interv later dose dose week prior weeksind approvedprevent rotaviru gastroeneter caus serotypesprevent rotaviru gastroeneter caus serotypespric per cours
privat market dengue-endem region also travel vaccin
estim total dengu market
rsv major caus morbid newborn young children age popul
sometim result mortal rsv common respiratori pathogen
infant hospit year alon
hospit global rsv infect occur adult
 year result hospit estim total rsv
market june manag highlight two-prong approach
passiv immunolog approach long-act monoclon antibodi
neutral viru pediatr segment rna-vaccin approach
collabor
investor day june liken cmv today rubella
common non-genet caus neurolog disabl young children hear loss
identifi govern agenc regulatori author area
unmet medic need prevent measur estim
global market view industry-lead first-in-class cmv
vaccin early-phas data suggest abil gener clinic meaning immun
merck anim health third-largest player anim health
sale portfolio well diversifi balanc mix companion anim
food anim segment robust pipelin may merck receiv fda
approv bravecto fluralan chewabl flea tick tablet use dog
anim health expert believ merck anim health well posit grow
organ failur combin merial refocus attent grow
oper margin current low rang merck said evalu strateg
option busi howev recent said would keep unit
merck anim health continu add bolt-on acquisit march complet
acquisit valle lead brazilian anim health compani
valle portfolio includ product encompass area paraciticid anti-
infect vaccin acquisit boost merck presenc latin america
major supplier world meat product april merck complet
acquisit antelliq global leader anim digit track monitor
approxim includ debt digit monitor grow area
livestock efficiently/tim assess health/act pet increas
medic forecast anim health sale
impli compound growth line
expect market growth
nuvar intra-vagin contracept nuvar insert day new
ring insert break insert ring issu nuvar
excel bleed profil favor side-effect profil conveni made
contracept choic patient physician one side-effect
increas vagin discharg associ decreas bacteri
vaginosi report suggest thromboembol side-effect profil line low dose
ocp nuvar also use off-label week patent expir
april first gener approved/launch decemb
addit gener approv expect estim nuvar sale
vytorin ezetimib simvastatin demonstr signific lower power
initi support cv outcom data chang base posit
surround vytorin zetia ezetimib reflect fact zetia perform
poorli imt trial enhanc despit signific ldl-lower
skeptic believ zetia mechan lower level
differ statin despit much skeptic improve-it two activ arm
enrol patient alreadi low achiev cv benefit ezetimib
ad statin improve-it achiev endpoint intent-to-treat basi
on-treat result even stronger merck file mace reduct zetia
vytorin april base improve-it howev februari merck receiv
propos label updat follow decemb adcom meet
support cv benefit claim merck announc next step
 patent zetia expir april although agreement allow
glenmark gener launch decemb vytorin gener launch
forecast zetia sale
vytorin sale forecast
decemb fda adcom vote includ cv benefit claim current
zetia vytorin label base improve-it trial fifteen panelist
conclud trial provid substanti evid ad ezetimib
statin simvastatin reduc risk cv event panelist note
reduct risk cv death mi unstabl angina coronari
revascular stroke primari endpoint statist signific
persuas addit panelist rais sever concern risk reduct
driven non-fatal mi stroke versu mortal benefit occur almost
exclus patient either diabet least year age
unfavor imbal hemorrhag stroke observ treatment vs
benefit observ global popul patient
enrol estim manag miss data
due dropout
singulair montelukast one-tim asthma control global asthma
awaken reduc asthma attack improv qualiti life safe side-effect
profil singulair also market treatment symptom season
allerg rhiniti sar also known hay fever perenni allerg rhiniti indoor
allergi adult children month age older exercise-induc
bronchoconstrict physician expert view singulair modestli effect
sar singulair patent expir eu japan
may fda panel reject propos over-the-counter use singulair allerg
rhiniti adult yr older panel express concern potenti off-label
use pediatr asthma patient well neuropsychiatr side effect panel
believ issues/risk could adequ address label
neuropsychiatr event remain overhang review septemb
pediatr fda adcom panel support fda prefer ad mandatori
medic guid rather black box warn label despit sale over-the-counter
busi bayer merck retain right singulair over-the-counter forecast singulair sale
dulera foradil/mometason combin approv
treatment asthma children year age august label
expand includ use children young year old dulera avail mdi
dose counter dose twice-daili ident advair gsk
symbicort azn less conveni once-daili breo gsk merck
withdrew eu market applic asthma due inabl provid request
data time-frame requir
dulera/zenhal approv asthma ou market launch copd
four ou market howev sale estim dulera sale
nasonex mometason furoat monohydr nasal spray growth slow due
avail gener corticosteroid spray gener flonas competit
corticosteroid spray gsk veramyst march first gener
version launch apotex fda deni merck petit approv
gener version slightli differ formul previou court decis
upheld nasonex patent valid also rule apotex version
infring merck appeal injunct grant apotex sandoz gener
version launch other expect eu gener launch april
august merck announc agreement exclus right
 pursu regulatori approv nasonex over-the-counter spray term disclos
nasonex sale forecast
februari merck enter agreement samsung bioepsi
develop manufactur commerci biosimilar candid
anti-tnf merck commerci right area except eu
russia turkey date collabor receiv approv five biosimilar
septemb merck/samsung receiv first biosimilar approv
enbrel biosimilar korea trade name brenzi
approv eu benepali australia canada decemb
remicad biosimilar approv korea receiv
approv eu australia approv april
renflexi launch juli discount refer product humira
biosimilar imraldi approv korea august eu august
launch pend market evalu tent approv grant juli
final approv key end stay post sanofi septemb
lawsuit march howev octob compani announc
termin agreement insulin glargin base assess market
environ potenti product collabor remain intact ontruz
biosimilar herceptin approv europ novemb merck
commerci launch time unclear biosimilar avastin file
novemb per merck biosimilar revenu
compani data cowen compani estim
 short-term account current properti plant intang long term long-term long-term short-term account current current long-term defer incom long-term long-term actual yet avail
compani data cowen compani estim
compani data cowen compani estim
current current liabil work capit ex actual yet activ net incom depreci chang work capit adjust net activ capit acquisitions/divestitur purchas /sale activ net debt share repurchas chang actual yet avail
compani data cowen compani
assumptionsoutputequ share outstand gross margin oper interest incom tax work free adjust estimatesmerck dcf
olaparib oral parp inhibitor approv
breast ovarian cancer file china
gbrca metastat breast cancer
pembrolizumab approv
tumor type multipl pii/iii mono
combo studi collabor sever
combo w/ pembro select solid tumor
pi combo nivolumab w/eisai
tumor combo w/ tagrisso nsclc pi
combo w/ durvalumab solid tumor
azn
coxsackieviru anti-
tumor activ intraven
pi combo w/ keytruda
earli data esmo pi solid tumor
nsclc combo w/ keytruda
pi mono combo w/
inhibitor rcc peloton
inhibitor rcc peloton
sting agonist mono combo w/
keytruda solid tumor
advanc solid tumor combo w/
anti-tigit pi mono combo w/
keytruda earli data
combo w/ keytruda solid tumor
variou cancer autoimmun diseas
victoria trial data w/ bayer
alzheim diseas licens teijin
approv diabet eu
investig mab pi
nash licens
fumar infect approv
 eu expect label updat switch
approv eu
approv june habp/vabp
design approv
adult complic uti intra-
on-going piii ped gram-neg
nnrti hiv data combo
total drug develop
marker count toward column total advanc phase
cowen compani
cough includ cough idiopath
endpoint reduct awak cough
newlink genet piii began march
interim piii analysi guinea
design piii adult
inactiv vzv vaccin develop
hold due competit environ
target epidemiolog adult
